Unit dose oral care compositions comprising fluoride
The unit dose oral care composition addresses the challenge of fluoride ion reactivity in dentifrice by minimizing interactions with other components, achieving rapid and complete fluoride release, thereby maintaining effective anti-caries benefits.
Patent Information
- Application Number
- CN202380032392.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-19
- Filing Date
- 2023-04-03
- Publication Date
- 2024-12-06
AI Technical Summary
Existing dentifrice compositions face challenges in incorporating fluoride ions due to chemical reactivity with other components, leading to variable bioavailability and difficulty in achieving rapid and complete release into the oral cavity, which affects anti-caries efficacy.
A unit dose oral care composition is developed with a non-inferior dose of fluoride, ensuring minimal reactivity between fluoride ions and other components, and designed for rapid and complete release into the oral cavity, maintaining bioavailability at least 60% of the salivary fluoride pharmacokinetic area under the curve (pK AUC) of a reference toothpaste.
The composition ensures effective delivery of fluoride ions, maintaining at least 60% of the salivary fluoride pharmacokinetic area under the curve (pK AUC) of a reference toothpaste, enhancing anti-caries benefits by minimizing reactivity and ensuring rapid dispersion and deposition into the oral cavity.
Smart Images

Figure BDA0005069830180000061 
Figure BDA0005069830180000241 
Figure BDA0005069830180000242
Abstract
Description
Technical Field
[0001] The present disclosure relates to unit dose oral care compositions comprising fluoride and / or fluoride ions and methods of use thereof. The present disclosure also relates to unit dose oral care compositions comprising a non-inferior (NI) dose of fluoride relative to a dentifrice paste. Background Art
[0002] Dentifrice compositions are typically formulated as pastes that can be squeezed out of tubes. Dentifrice compositions may contain metal ions, fluoride ions, abrasives, calcium sources, surfactants, whitening agents, humectants, thickeners, and other formulation ingredients. Typically, dentifrice compositions must be carefully formulated to avoid reactivity in the tube, but to maintain reactivity in the oral cavity. In many cases, ingredients must be replaced or removed to balance reactivity in the tube with beneficial effects in the mouth.
[0003] In particular, fluoride ion sources (such as sodium fluoride, stannous fluoride and / or sodium monofluorophosphate, etc.) can be added to dentifrice compositions to deliver anti-caries benefits. However, due to the reactivity between fluoride ions and other dentifrice components (such as calcium ions), fluoride ion sources may be difficult to incorporate into dentifrice and / or oral care compositions. One method of reducing reactivity is to remove water from toothpaste to obtain a compacted toothpaste dosage form. These compacted doses can be unitized in addition. Similar to the reference dentifrice composition, it is important and difficult to produce a hydrate and release fluoride into the oral cavity in a compacted combined dose.
[0004] Fluoride ions provide anti-caries benefits by being taken up into the enamel. Fluoride interacts with the mineral component of teeth (called hydroxyapatite or HAP) through the OH - F - Fluoride is substituted to produce fluorohydroxyapatite (FAP) mineral. Fluoride incorporation into tooth enamel as FAP results in increased hydrogen bonding, a denser lattice, and an overall decrease in enamel solubility. Incorporation of fluoride into the hydroxyapatite (HAP) lattice can occur when the tooth is forming or after it has grown out through ion exchange. In addition, enamel solubility decreases with increasing fluoride incorporation. Therefore, fluoride is routinely added to dentifrices and mouthwashes to strengthen the enamel of teeth.
[0005] Unfortunately, fluoride bioavailability can vary significantly due to: (i) chemical reactivity between fluoride ions and other components (such as calcium ions, abrasive systems, chelating agents, and whitening agents), (ii) hydrolysis, and (iii) oxidation. Thus, depending on the concentration and presence of other reactive components, the fluoride bioavailability of fluoride ions in the paste is affected over time, since many fluoride compounds are susceptible to hydrolysis and / or reaction when in the aqueous phase.
[0006] Dentifrice compositions must also be carefully formulated to ensure rapid dispersion and release of the ingredients into the oral cavity. In addition, dentifrice compositions are often designed to release active ingredients in a manner that is non-inferior to clinically relevant benchmarks to ensure clinical efficacy without the need for lengthy clinical trials. The ability of a dentifrice composition to rapidly disperse and deposit non-inferior amounts of fluoride into the oral cavity relative to relevant clinical benchmarks is an important way to ensure efficacy of the composition.
[0007] In particular, fluoride ion sources such as sodium fluoride, stannous fluoride and / or sodium monofluorophosphate can be added to dentifrice compositions to deliver anti-caries benefits. However, fluoride ion sources can be difficult to incorporate into dentifrice and / or oral care compositions while ensuring rapid release from the composition and dispersion to the oral surfaces.
[0008] Incorporation of fluoride ions into dentifrice compositions is only possible by minimizing the interaction between fluoride ions and other dentifrice components during storage to maximize the availability of fluoride ions for reactivity with oral surfaces such as enamel, dentin, gums, plaque, and bacteria, and then releasing and dispersing the fluoride ions into the oral cavity in a manner that is non-inferior to clinically relevant benchmarks such as the USP reference dentifrice to ensure anticaries efficacy. Therefore, there is a need for an oral care composition that minimizes the reactivity between a fluoride ion source and other dentifrice components and also rapidly releases and disperses the fluoride ions into the oral cavity in a manner that is non-inferior to clinically relevant benchmarks. Summary of the invention
[0009] Disclosed herein is a unit dose oral care composition comprising fluoride, wherein the unit dose oral care composition has a salivary fluoride pK AUC that is at least 60% of the salivary fluoride pharmacokinetic area under the curve (pK AUC) of a reference toothpaste. DETAILED DESCRIPTION
[0010] Embodiments of the present invention are directed to unit dose oral care compositions comprising a non-inferior dose of fluoride. Unfortunately, the release and dispersion of fluoride from an oral care composition can be significantly altered by (i) the presence of excipients, (ii) the dosage form, (iii) the concentration of fluoride, (iv) the dose of fluoride, (v) the distribution of fluoride in a heterogeneous composition, and (vi) the manufacturer's instructions. As a result, the delivery of fluoride ions to the oral cavity of a solid or semisolid unit dose oral care composition may be less than expected. Therefore, the present application is directed to a unit dose oral care composition comprising a higher dose (i.e., a non-inferior dose) of fluoride to allow rapid and complete release of fluoride into the oral cavity.
[0011] definition
[0012] In order to more clearly define the terms used herein, the following definitions are provided. Unless otherwise indicated, the following definitions all apply to the present disclosure. If a term is used in the present disclosure but is not specifically defined herein, the definition from IUPAC Compendium of Chemical Terminology 2nd edition (1997) may be applied, as long as the definition does not conflict with any other disclosure or definition used herein, or does not make any claim to which the definition is applied uncertain or incapable of being realized.
[0013] As used herein, the term "oral care composition" refers to a product that is retained in the oral cavity for a sufficiently long time to contact some or all of the tooth surface and / or oral tissue for the purpose of oral health during common use. In one embodiment, the composition is retained in the oral cavity to deliver an oral care active agent. The oral composition according to an embodiment of the present invention can be in various forms, including toothpaste, dentifrice, tooth gel, tooth powder, tablet, mouthwash, subgingival gel, foam, mousse, chewing gum, lipstick, sponge, dental floss, polishing paste, vaseline gel, denture products, nonwoven fiber web or foam. In one embodiment, the oral composition is in the form of a nonwoven fiber web. In another embodiment, the oral composition is in the form of a dentifrice. The oral composition can also be incorporated into a strip or film for direct application or adhesion to the oral surface or incorporated into the dental floss. The oral care composition can also be a strip that can be directly applied to the oral surface. The strip can be at least partially dissolved when contacting with moisture or brushing teeth.
[0014] As used herein, the term "orally acceptable carrier" refers to suitable vehicles and ingredients that can be used to form the compositions of the present invention and / or administer the compositions of the present invention to the oral cavity in a safe and effective manner.
[0015] As used herein, the term "effective amount" refers to an amount of a compound or composition sufficient to cause a positive beneficial effect, an oral health benefit, and / or an amount low enough to avoid serious side effects, i.e., to provide a reasonable benefit-risk ratio within the reasonable judgment of a skilled person. Depending on the type of oral health benefit and the efficacy of the active compound, an "effective amount" refers to at least about 0.0001% of the material, 0.001% of the material, or 0.01% of the material by weight of the composition.
[0016] As used herein, unless otherwise indicated, the term "dentifrice" refers to a paste, gel, powder, tablet, disc, sheet, film, or liquid preparation used to clean, treat, or contact the oral surfaces. Additionally, as disclosed herein, a dentifrice refers to a nonwoven web used to clean the oral surfaces. As used herein, the term "tooth" refers to natural teeth as well as artificial teeth or dentures.
[0017] As used herein, the term "filament" refers to a thin, flexible, thread-like object that can be used to form a nonwoven web of the type of the present invention. The length of the filament can greatly exceed its diameter, that is, the ratio of length to diameter is at least about 5, 10 or 25.
[0018] The filaments of embodiments of the present invention may be spun from a nonwoven web-forming material via a suitable spinning operation such as meltblowing or spunbonding.
[0019] It is generally believed that filaments are substantially continuous or substantially continuous. Filaments are relatively longer than fibers. Non-limiting examples of filaments may include meltblown filaments, spunbond filaments, and combinations thereof. In one embodiment, the filaments are meltblown filaments.
[0020] In one example, the filaments may be in the form of fibers, such as when the filaments are cut into shorter lengths. Thus, in one example, embodiments of the present invention also include fibers comprising the filaments.
[0021] As used herein, "nonwoven web-forming material" refers to a composition suitable for preparing filaments such as by meltblowing, spunbonding or fluid film fibrillation. The nonwoven web-forming material includes one or more nonwoven web-forming materials that exhibit properties that make them suitable for spinning into filaments.
[0022] As used herein, the "length" of a filament refers to the length from one end to the other end along the longest axis of the filament. If the filament has a knot, curl or bend in it, the length is the length along the complete line of the filament.
[0023] As used herein, "average diameter" with respect to filaments is measured according to the Diameter Test Method described herein.
[0024] As used herein, the terms "disintegrable" and "disintegrate" refer to the reduction of an oral care composition, filament, or nonwoven fabric into components, fragments, or compositions when exposed to conditions of intended use.
[0025] As used herein, the term "dissolved" refers to the solubilization of the oral care composition, filaments or nonwoven web, either in large part or in full. The oral care composition may appear to be visibly dissolved even if some components are not completely dissolved, such as a cross-linked polyacrylic acid polymer forming a clear gel that provides the appearance of being dissolved, while not being bound by theory, the clear gel is simply hydrated. Another example is an abrasive that may constitute a large part of the composition but does not dissolve at all. If only the abrasive has not yet dissolved, the oral composition comprising the abrasive will still be considered "dissolved".
[0026] As used herein, the term "applying" includes spraying, dusting, showering, coating, surface printing (e.g., in the shape of a desired decoration, ornament or pattern), pouring, injecting into, dipping or by any other suitable means, such as by using a depositor, screen or powder bed.
[0027] As used herein, "intended use conditions" refers to the temperature conditions, physical conditions, chemical conditions and / or mechanical conditions to which an oral care composition comprising one or more filaments of the present invention is exposed when the oral care composition is used for its designed purpose. The oral care composition of the present invention can be applied to a mammal via the oral cavity, mouth, throat, and combinations thereof. The intended use conditions can be the temperature, physical, chemical and / or mechanical conditions in the oral cavity, mouth and / or throat of a mammal.
[0028] As used herein, "triggering condition" refers to any action or event that acts as a stimulus and initiates or promotes a change in the filament, such as loss or change in the physical structure of the filament and / or release of oral care active substances, including dissolution, disintegration, hydration and swelling. Some triggering conditions include suitable pH, temperature, shear rate or water content.
[0029] As used herein, "morphological change" about the morphological change of long filament refers to the change of its physical structure in long filament. The non-limiting example of the morphological change of long filament according to an embodiment of the present invention includes dissolving, melting, swelling, shrinking, breaking into pieces, disintegrating, lengthening, shortening, peeling, splitting, shredding, implosion, twisting and their combination. When long filament is exposed to the intended use condition, this long filament can completely or substantially lose its long filament physical structure or this long filament can have its morphological change or can keep or substantially keep its long filament physical structure.
[0030] As used herein, "web" means a sheet of continuous filaments or fibers of any nature or origin that have been formed into a web by any process and bonded together by any means.
[0031] As used herein and defined by the European Disposables and Nonwoven Fabrics Association (EDANA), "nonwoven web" refers to a continuous filament sheet or continuous fiber sheet of any nature or source that has been formed into a web by any means and has been bonded together by any means, but except weaving or knitting. The felt obtained by wet grinding is not a nonwoven fabric. In one example, a nonwoven web according to an embodiment of the present invention refers to an orderly arrangement of filaments in a structure to perform a function. In one example, a nonwoven web according to an embodiment of the present invention is an arrangement comprising multiple two or more and / or three or more filaments, which are entangled with each other or otherwise associated with each other to form a nonwoven web.
[0032] Unless otherwise specified, all percentages and ratios used hereinafter are by weight of the total composition. Unless otherwise specified, the percentages, ratios and levels of all ingredients mentioned herein are based on the actual amount of the ingredient, and do not include solvents, fillers or other substances that may be used with these ingredients in commercially available products. Unless otherwise specified, all measurements referred to herein are performed at 25°C.
[0033] Compositions, processes and methods according to embodiments of the present invention may comprise, consist of, or consist essentially of the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components or limitations described herein or otherwise useful in oral care compositions intended for use or consumption by mammals, preferably humans.
[0034] An oral care composition having a "non-inferior" (NI) dose of an active agent (such as an anticaries drug) is defined herein to mean that the performance of the experimental product is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90% of the performance of the reference product. The reference product used herein is the United States Pharmacopeia (USP) Dentifrice Control (USP, Rockville, MD, USA), as indicated where appropriate. According to Table A below, appropriate reference formulations vary depending on the experimental test product and may include commercial products if the USP control is not available for any reason.
[0035] Table A
[0036]
[0037] In order to compare the performance of a given product with that of a reference product, the therapeutic quality of the reference product is used. For the purpose of the following examples, the quality used to determine whether the oral care composition is not inferior to the reference product in terms of its active agent delivery is about 1g or about 1.25g of the reference product per dose (single brushing event). There is no generally accepted standard for how much quality of toothpaste is used as a given amount in a single brushing event. Various studies have used 1g, 1.25g and 1.5g as therapeutic quality. For example, the new drug application supporting triclosan as an anti-gingivitis agent in toothpaste limits the mass of toothpaste per brush to 1.25g. In various embodiments, in the brushing event for adults and children greater than about 7 years old, greater than about 8 years old, greater than about 9 years old or greater than about 10 years old, the appropriate dose of toothpaste can be in the range of about 1g to about 1.5g, about 1.1g to about 1.4g, about 1.2g to about 1.3g, or can be about 1g or about 1.25g.
[0038] Unit dose oral care composition
[0039] The oral care composition according to an embodiment of the present invention may be a unit dose oral care composition. A unit dose oral care composition is the amount of oral care composition that will be administered to a patient or consumer in a single use. The unit dose oral care composition may be a unit dose dentifrice, a unit dose mouthwash, a unit dose tooth gel, a unit dose tooth whitening composition, or any other suitable unit dose oral care composition that can be retained in the oral cavity for a sufficient period of time to contact some or all of the tooth surfaces and / or oral tissues to achieve the purpose of oral health.
[0040] The amount (by mass and / or volume) of the unit dose oral care composition is determined based on the desired type of the unit dose oral care composition. For example, a unit dose dentifrice may be formulated to deliver the correct amount of fluoride in a single use, depending on local laws and regulations. In addition, the size of the unit dose dentifrice may be set to deliver the correct amount or ratio of other ingredients, such as, for example, antimicrobial agents, abrasives, surfactants, flavors, metal ions, etc. Similarly, the size of the unit dose mouthwash may be set to deliver the correct amount of mouthwash ingredients, such as, for example, fluoride ions, antimicrobial agents, abrasives, surfactants, flavors, metal ions, etc.
[0041] The unit dose oral care composition can be in the form of a pouch, droplets, solid open-cell foam, solid closed-cell foam, a fibrous composition, a paste composition, a gel composition, a tablet composition, a bar composition, a ribbon composition, and / or a composition in one or more of the forms described in this paragraph.
[0042] The unit dose oral care composition may be sized to fit a manual toothbrush, a powered toothbrush, or any other applicator designed to facilitate contacting the unit dose oral care composition with oral surfaces, including but not limited to teeth.
[0043] The unit dose oral care composition according to an embodiment of the present invention can be a substantially flat or flat composition in the form of a pad, strip, tape or tablet, and the substantially flat or flat composition has a thickness of about 0.05 millimeters (mm) to about 20 mm, about 0.05 mm to about 10 mm, about 0.05 mm to about 5 mm, about 0.5 mm to about 1 mm, about 0.05 mm to about 0.5 mm, about 0.05 mm to about 0.25 mm or about 0.05 mm to about 0.1 mm, as measured by the thickness method described below. The unit dose oral care composition can be formed into a cylindrical shape (e.g., by rolling) with a length of about 0.5 centimeters (cm) to about 10 cm, about 1 cm to about 5 cm or about 1.5 cm to about 3 cm. The unit dose oral care composition can be a rectangular prism including a cube, wherein the longest side of the rectangular prism has a length of about 5 mm to 20 mm, about 10 mm to 15 mm or about 5 mm to about 10 mm, as measured by the thickness method described herein. If the size of the dose is changed, the basis weight of the dose may be changed. The unit dose oral care composition may be circular or oval, wherein the diameter of the circle or the length of the longest part of the oval is from about 5 mm to about 5 cm, 5 mm to about 100 mm, 5 mm to about 50 mm, 1 cm to about 5 cm, or 100 mm to about 1 cm.
[0044] The unit dose oral care composition can be in the form of one or more flat sheets or pads, which have sufficient size to be easily handled by the user. The unit dose oral care composition can contain a unit dose of one or more oral care active substances, which can provide one or more oral care benefits and / or treat one or more oral care disorders. The unit dose oral care composition can have a square, rectangular, oval, circular, disc-shaped or any other suitable shape. The unit dose oral care composition can also be in the form of a continuous strip, including delivery on a strip-like roller dispenser, which has individual portions dispensed via perforations and / or cutting mechanisms.
[0045] A unit dose oral care composition may allow for the dose to contain incompatible components within the same composition. Components are considered incompatible with one another if at least one of the components has a significant reduction in efficacy, stability, or bioavailability when the components are in the same solution or as a non-solid mixture. Incompatible components may be components that chemically interact with one another to form new compounds, complexes, and / or salts and / or components that will separate into discrete parts or phases of the composition to minimize adverse interactions.
[0046] Examples of incompatible components may include, but are not limited to, a metal ion source and a silica abrasive, a metal ion source and a polyphosphate, a metal ion source and a pyrophosphate, a calcium ion source and a fluoride ion source, a calcium ion source and a phosphate, a calcium ion source and a pyrophosphate, an oxalate ion and a peroxide compound, a stannous fluoride and a peroxide compound, a cationic antimicrobial agent (such as cetylpyridinium chloride) and a fluoride ion source, an acid and a base, a calcium ion source and a chelating agent (such as EDTA), an oxidizing agent and a reducing agent, a hydrophobic component (such as petrolatum, silicone, polybutene) and a hydrophilic component (such as water and alcohol), and / or any other incompatible component as defined above.
[0047] The unit dose oral care compositions described herein can be designed to maximize the bioavailability, stability and / or efficacy of the ingredients by minimizing the reactivity between the ingredients. Minimizing the reactivity between the ingredients can be achieved by physically separating the ingredients into discrete parts of the composition or by placing one or more ingredients in a less reactive solid phase.
[0048] In the context of a pouch composition, the interior volume can be divided into a plurality of discrete, layered, adjacent and / or overlapping portions, and the pouch composition can place one or more components in each portion. For example, a fluoride ion source can be in one portion of the pouch composition, while a calcium ion source can be in another portion of the pouch composition. Additionally, a metal ion source can be in one portion of the pouch composition, while a silica abrasive or a polyphosphate can be in another portion of the pouch composition.
[0049] In the context of fiber oral care composition, one or more reactive components can be in a nonwoven fiber web layer, and one or more reactive components can be in another nonwoven fiber web layer. In addition, one or more reactive components can be present in one or more nonwoven fiber web layers, and one or more reactive components can be between the one or more nonwoven fiber web layers, on the top of the one or more nonwoven fiber web layers, below the one or more nonwoven fiber web layers, folded in the one or more nonwoven fiber web layers, adjacent to the one or more nonwoven fiber web layers, or overlapped with the one or more nonwoven fiber web layers, such as in non-fibrous composition. For example, a fluoride ion source can be spun in the first fiber composition comprising one or more nonwoven fiber web layers or mixed with the first fiber composition, and a calcium ion source can be spun in the second fiber composition comprising one or more nonwoven fiber web layers or mixed with the second fiber composition. Any suitable mode can be used to assemble the first fiber composition and the second fiber composition into a single multilayer composition. In addition, the fluoride ion source can be spun into or mixed with the fiber composition comprising one or more nonwoven fiber web layers, and the calcium ion source can be present in the non-fibrous composition as a solid composition or at least partially dissolved or at least partially dispersed in a liquid composition. The fiber composition and the non-fibrous composition can be assembled into a multi-layer composition, or the non-fibrous composition can be between the fiber compositions, on top of the fiber composition, below the fiber composition, folded into the fiber composition, adjacent to the fiber composition, or superimposed with the fiber composition.
[0050] In the context of a foam oral care composition such as a flexible porous dissolvable solid structure, the reactive components may be within an open-cell foam or a closed-cell foam, or mixed together within an open-cell foam or a closed-cell foam, the foam composition being described in U.S. Patent Application No. 2011 / 0027328, which is incorporated herein by reference. One or more reactive components may be present in the foam composition, while one or more reactive components may be present in a non-foam composition (such as a surface-resident particle coating) coating the surface of the solid foam composition.
[0051] As described herein, the use of unit dose oral care compositions allows for ease of portability and the ability to better control dosage. For example, due to current restrictions on liquid products for airlines, a passenger is limited to carrying only a small amount of mouthwash or dentifrice, or is limited to packing his mouthwash or dentifrice in his checked luggage. If the oral care composition is in unit dose form, the passenger can pack exactly the required amount into the carry-on luggage without having to worry about airline packing restrictions.
[0052] Fiber oral care composition
[0053] The oral care composition may be a fibrous oral care composition. The fibrous oral care composition may include a fibrous composition and / or a non-fibrous composition. The fibrous composition may include at least one fibrous web. The fibrous composition may include a nonwoven fibrous web and / or a woven fibrous web.
[0054] The fiber composition may include one or more fiber web layers. The one or more fiber web layers may include one or more filaments and / or fibers. The oral care composition may include a first fiber web and a second fiber web, wherein the first fiber web and the second fiber web include different components.
[0055] The fiber composition may include any suitable oral care components.The fiber composition may include any of the components described herein.
[0056] The fiber web may include more than one filament. The fiber web may include a first filament and a second filament each including an oral care active, and the oral care active may be the same oral care active or different oral care actives. The fiber web may include: a first filament including an immediate delivery oral care active; and a second filament including an extended delivery, delayed delivery, and / or directed delivery oral care active. The fiber web may include a first filament, a second filament, and a third filament, wherein each filament includes a different oral care component.
[0057] From the perspective of composition, a fiber web or oral care composition may include multiple identical or substantially identical filaments according to an embodiment of the present invention. A fiber web or oral care composition may include two or more different filaments. Non-limiting examples of filament differences may be physical differences, such as differences in diameter, length, texture, shape, hardness, elasticity, etc.; chemical differences, such as cross-linking level, solubility, melting point, glass transition temperature (Tg), fiber web forming material, color, amount of oral care actives, amount of fiber web forming material, presence of coating composition on oral care composition, chemical composition of oral care actives including whether oral care actives are delivered immediately, delayed, extended or directional, etc.; differences in whether the filaments lose their physical structure when exposed to the intended use conditions; differences in whether the filaments change their morphology when exposed to the intended use conditions; and differences in when and where the beneficial effects from oral care actives are experienced. In one example, two or more filaments in an oral care composition or fiber web may include the same fiber web forming material, but have different oral care actives.
[0058] The fiber web may comprise two or more filaments, wherein the filaments release oral care actives at different rates. The different rates may be caused by the filaments being positioned at the outer surface of the fiber web.
[0059] The oral care composition may include a non-fibrous composition, which may or may not be greater than the fibrous composition in weight percentage by weight of the oral care composition. The non-fibrous composition may be between the first fiber web and the second fiber web. At least a portion of the non-fibrous composition may be in contact with the surface of the fibrous composition. The non-fibrous composition may be placed on a single fiber web layer, and the fiber web layer may be folded on top of the non-fibrous composition, rolled with the non-fibrous composition, placed on top of or below the fibrous composition, and / or the fibrous composition may wrap the fibrous composition.
[0060] The non-fibrous composition may include any suitable oral care component.The non-fibrous composition may include any component described herein.The non-fibrous composition may be liquid, solid, aqueous, and / or combinations thereof.
[0061] The oral care composition according to an embodiment of the present invention may have a thickness of about 10 grams per square meter (g / m 2 ) to about 5000g / m 2 , about 25g / m 2 About 2500g / m 2 , about 40g / m 2 About 1500g / m 2 or about 500g / m 2 About 2000g / m 2 The basis weight.
[0062] The fibrous oral care composition may include two or more components or oral care actives that are generally considered incompatible as described herein. For example, the first fiber web layer may include a fluoride ion source, and the second fiber web layer may include a calcium ion source. In another example, the first fiber web layer may include a metal ion source, such as a stannous ion source, and the non-fibrous composition may include a silica abrasive or a polyphosphate.
[0063] The oral care composition or fibrous web may exhibit distinct regions, such as regions of different basis weight, density, and / or thickness.The oral care composition or fibrous web may include discrete regions of filaments that are distinct from other portions of the fibrous web.
[0064] The oral care composition or web may include one or more textured, concave or topographically patterned surfaces, including letters, logos or numbers. The textured oral care composition may result from the shape of the filaments or web, in that the outermost surface of the composition includes portions that are raised relative to other areas of the surface. The raised portions may result from the formed shape of the oral care composition, for example, the web may be formed into a concave or grid-like pattern. The raised portions may also be the result of a creping process, a printed coating, an embossed pattern, or the physical form of the composition itself.
[0065] The fiber web according to an embodiment of the present invention can be pressed into a film to form an oral care composition; this can be accomplished by applying a compressive force and / or heating the fiber web to convert the fiber web into a film. The film may contain oral care active substances present in the filaments. The fiber web can be completely converted into a film, or portions of the fiber web can remain in the form of a film after the fiber web portion is converted into a film. The oral care composition may consist of one or more fiber webs, at least one of which has been pressed into a film. The oral care composition may include two or more fiber webs that have been pressed into a film.
[0066] The fiber web can be rolled, compressed, cut or stacked to form a three-dimensional oral care composition. For example, the fiber web can be pressed into a pill or tablet, rolled into a cylinder or compressed or stacked into a rectangular prism to form an oral care composition.
[0067] The oral care composition may comprise one or more fibrous web layers, which are optionally bonded together via bonding methods including heat, moisture, ultrasound, pressure, etc. The oral care composition may comprise one or more fibrous web layers, which are optionally bonded together via compression.
[0068] The oral care composition or nonwoven web may be fully or partially perforated with holes or passages for entering or passing through the oral care composition in one or more web layers. These perforations may be formed as part of preparing the web or oral care composition via spikes extending from the surface of an adjacent belt, drum, roller, or other surface. Alternatively, these perforations may be formed after the web or oral care composition is formed by poking or piercing a porous solid with a pin, needle, or other sharp object.
[0069] Filament
[0070] The oral care composition may comprise one or more filaments. In various embodiments, the filaments exhibit a length greater than about 0.1 inches, greater than about 0.2 inches, greater than about 0.3 inches, or greater than about 2 inches.
[0071] Long filament can have the average diameter less than about 150 microns (μm), less than about 100 μm, less than about 10 μm or less than about 1 μm, wherein the relative standard deviation is less than 100%, less than 80%, less than 60% or less than 50%, such as in the range of 10% to 50%.As described herein, significant number refers to at least 10% of all long filaments, refers to at least 25% of all long filaments in another embodiment, refers to at least 50% of all long filaments in another embodiment, refers to at least 75% of all long filaments in another embodiment.Significant number can be at least 99% of all long filaments.At least 50% of all long filaments can have the average diameter less than about 10 μm.The long filament produced by the method of the present disclosure can have the filament or submicron filament of the average diameter less than about 1 μm of significant number. In one embodiment, the oral care composition may comprise at least 25% of all filaments having an average diameter less than about 1 μm, at least 35% of all filaments having an average diameter less than about 1 μm, at least 50% of all filaments having an average diameter less than about 1 μm, or at least 75% of all filaments having an average diameter less than about 1 μm.
[0072] The filaments may contain less than 30% moisture by weight of the filament, less than 20% moisture by weight of the filament, less than about 10% moisture by weight of the filament, less than about 5% moisture by weight of the filament, less than about 3% moisture by weight of the filament, less than about 1% by weight of the filament, or less than about 0.1% moisture by weight of the filament.
[0073] The filaments according to the embodiments of the present invention may be monocomponent and / or multicomponent. The filaments may be bicomponent filaments. The filaments may be tricomponent filaments. The multicomponent filaments may be in any form, such as side-by-side, core-sheath, island-in-the-sea, etc.
[0074] The filaments may be meltblown filaments. The filaments may be spunbond filaments. The filaments may be hollow filaments before and / or after releasing the active agent of one or more filaments.
[0075] The filaments may comprise an oral care active within the filaments and an oral care active on the outer surface of the filaments (such as a coating on the filaments). The oral care active on the outer surface of the filaments may be the same as or different from the active agent present in the filaments. If different, the oral care actives may be compatible or incompatible with each other.
[0076] Solid foam composition
[0077] The oral care composition may be a solid foam composition, such as the flexible porous dissolving solid structure described in US Patent Application No. 2011 / 0027328. The solid foam composition may be in the form of an open-cell foam or a closed-cell foam.
[0078] The solid foam composition may comprise any suitable oral care component. The solid foam composition may comprise any component described herein. The solid foam composition may comprise a surface-retaining coating composition. The surface-retaining coating composition may comprise any suitable oral care component or any component described herein.
[0079] Importantly, U.S. Patent Application No. 2011 / 0027328 does not disclose, teach, or suggest that the amount of pyrophosphate must be minimized in order to produce a solid soluble foam. In fact, U.S. Patent Application No. 2011 / 0027328 only teaches example foam compositions having large amounts of pyrophosphate. Thus, it was unexpectedly discovered herein that pyrophosphate interferes with the foam composition formation process.
[0080] Therefore, the solid foam composition according to an embodiment of the present invention comprises a foam-forming material, one or more surfactants, a plasticizer, and has less than about 5%, less than about 1% of inorganic metal salts, polyphosphates or, in particular, pyrophosphates, or is free of these substances. The foam-forming material is any suitable material that exhibits properties suitable for preparing foams. Non-limiting examples of foam-forming materials may include water-soluble polymers disclosed by U.S. Patent Application No. 2011 / 0027328.
[0081] Solid tablet composition
[0082] The oral care composition may be a solid tablet composition, such as a chewable or dissolvable tablet. Non-limiting examples of solid tablet compositions may include tablet compositions disclosed in U.S. Patent Application Publication Nos. 2004 / 0101493 and 2004 / 0101494, the entire contents of which are incorporated herein by reference.
[0083] The mechanical force of biting or chewing by the subject is used to deposit and retain the minimum amount of solid tablet composition on the tooth surface, especially in the pits, cracks and occlusal surfaces of the teeth. The tablet may contain a retaining agent and optionally one or more agents, such as oral care active agents, abrasives, foaming agents, flavoring agents / sensates and / or a specific buffer system. Then, the teeth can be brushed after the tablet is dissolved or disintegrated.
[0084] In embodiments where the oral care active dose is provided by one tablet, the tablet may be scored, wherein the subject splits the tablet in half and places 1 / 2 tablet on each side of the mouth before chewing. In embodiments where the oral care active dose is provided by two tablets, the subject may then place 1 tablet on each side of the mouth before chewing. Alternatively, when the appropriate dose is one tablet (twice a day), the subject may chew one tablet on one side of the mouth in the morning and the other tablet on the other side of the mouth in the evening.
[0085] In one embodiment, the solid tablet composition comprises a total unit dose weight in the range of about 100 mg to about 5 g, about 250 mg to about 2 g, or about 500 mg to about 1.5 g. The solid tablet composition can be any shape or size, for example, a spherical tablet or an ellipsoidal tablet. The solid tablet composition can be a compressed tablet or a molded tablet. Compressed tablets can be compressed using conventional equipment and processes. For molded tablets, the active agent can be incorporated into a substrate or coated onto a molded substrate during the molding process. The solid tablet composition can also be layered, including two or more layers.
[0086] In one embodiment of compressed dentifrice tablets, granulation of the dentifrice abrasive is necessary for the generally small particle size abrasives used. Granulation is preferred to provide flow for subsequent processing and to impart compactability to these materials. An exemplary granulation method is provided in U.S. Patent Application Publication No. 2004 / 0101493.
[0087] Tableting can be accomplished via conventional means, for example by compressing the final powder blend described above on a tablet press to form compacts having suitable properties, such as sufficient hardness and friability. Alternatively, if the blend of formulation components has adequate flow properties and reasonable compacts can be formed, direct compaction can be used, whereby the components are simply blended and tableted without the need for a granulation step.
[0088] Web-forming materials
[0089] The fiber web can be formed by any suitable means. The fiber web may include spun fibers and / or spun filaments. The nonwoven fiber web may be made of a fiber web forming material or a nonwoven fiber web forming material, as described in U.S. Patent Application Publication No. 2019 / 0233974, U.S. Patent Application Publication No. 2019 / 0233970, U.S. Patent No. 9,139,802, U.S. Patent No. 9,175,250 and / or U.S. Patent No. 8,785,361, which are incorporated herein by reference in their entirety.
[0090] The web-forming material may include any suitable material that exhibits properties suitable for preparing fibers or filaments. Non-limiting examples of web-forming materials may include polymers, polyols, sugars, sugar alcohols, and combinations thereof. The web may include two or more different web-forming materials. The web may include three or more different web-forming materials. Polymers may be used as web-forming materials and may also provide oral health benefits in certain embodiments.
[0091] The fiber composition may contain from about 1% to about 100%, from about 2% to about 50%, from about 5% to about 35%, from about 5% to about 20%, from about 1% to about 15%, or from about 5% to about 10% of the nonwoven web-forming material, based on the weight of the fiber composition.
[0092] The oral care composition may comprise from about 1% to about 80%, from about 1% to about 50%, from about 1% to about 25%, from about 2% to about 20%, from about 3% to about 15%, less than about 10%, or from about 5% to about 10% of a fiber web-forming material, based on the total weight of the oral care composition.
[0093] polymer
[0094] The oral care composition may include a polymer. The fiber web forming material may include a polymer. The fiber composition or the non-fiber composition may include a polymer. The foam composition may include a polymer. Non-limiting examples of polymers may include polymers of natural origin, synthetic polymers, and combinations thereof.
[0095] Non-limiting examples of naturally derived polymers may include alginates, gums, protein-based polymers, starch-based polymers, natural starches, modified starches, fiber polymers, other naturally derived polymers, and combinations thereof.
[0096] Non-limiting examples of alginates may include ammonium alginate, calcium alginate, potassium alginate, propylene glycol alginate, and combinations thereof.
[0097] Non-limiting examples of gums can include gum arabic, carrageenan, tragacanth gum, guar gum, locust bean gum, xanthan gum, gellan gum, and combinations thereof.
[0098] Non-limiting examples of protein-based polymers can include whey protein isolate, soy protein isolate, egg white protein, casein, collagen, gluten, gelatin, gluten protein, zein, and combinations thereof.
[0099] Non-limiting examples of starch-based polymers may include those derived from cereals, tubers, roots, legumes, fruits, and combinations thereof. Starch-based polymers may include glucose monomers linked in α1,4 bonds, amylose, amylopectin, and combinations thereof.
[0100] Non-limiting examples of natural starches can include waxy or high-amylase varieties of corn, peas, potatoes, bananas, barley, wheat, rice, sago, amaranth, cassava, arrowroot, canna, sorghum, and combinations thereof.
[0101] Non-limiting examples of modified starches may include hydroxypropyl starch, maltodextrin, high amylose starch, and combinations thereof.
[0102] Non-limiting examples of fiber polymers may include pectin, oligofructose, inulin, agar, beta-glucan, dextrin, lignin, cellulose, non-starch polysaccharides, reduced starch, polycarbophil, citrus fiber, and combinations thereof.
[0103] Non-limiting examples of other naturally derived polymers may include agar, pullulan, chitin, chitosan, shellac, and combinations thereof.
[0104] Non-limiting examples of synthetic polymers can include cellulose derivatives, carbomers, polymethacrylates, other synthetic polymers, and combinations thereof.
[0105] Non-limiting examples of cellulose derivatives may include hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl ethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof.
[0106] Non-limiting examples of carbomers may include carbomer 934, carbomer 934P, carbomer 940, carbomer 94, carbomer 1342, carbomer copolymers, carbomer homopolymers, carbomer interpolymers, and combinations thereof. Some carbomers are available under the trade name 934P NF polymer, 971P NF polymer and 974P NF polymer is commercially available.
[0107] Non-limiting examples of polymethacrylates may include ammonium methacrylate copolymers, basic butylated methacrylate copolymers, methacrylic acid-methyl methacrylate copolymers (1:1), methacrylic acid-ethyl acrylate copolymers (1:1), methacrylic acid-ethyl acrylate copolymers (1:1), methacrylic acid-methyl methacrylate copolymers (1:2), polyacrylate dispersion 30%, methacrylic acid copolymers, methacrylic acid amino ester copolymers, methacrylic acid amino ester copolymers, methacrylic acid amino ester copolymers, methacrylic acid amino ester copolymer dispersions, ethyl acrylate and methyl methacrylate copolymers, and combinations thereof. Some polymethacrylates may be found under the trade name E 12.5, E 100, EPO, L 12.5P, L 12.5, L 100, L 100-55, L 30D-55, S12.5P, S12.5, S100, FS30D, RL 12.5, RL 100, RL PO, RL 30D, RS12.5, RS100, RS PO, RS 30D, NE30D, NE 40D, NM 30D, Eazoryl TM 30D, MAE 30DP, MAE 100P, 93A and MP was purchased commercially.
[0108] Non-limiting examples of other synthetic polymers can include polyvinyl alcohol, carboxyvinyl polymer, polyvinyl pyrrolidone, polyethylene oxide, polyoxyethylene, and combinations thereof.
[0109] The polymer according to the embodiments of the present invention can be selected so that its weight average molecular weight is from about 20,000 Daltons (Da) to about 10,000,000 Da, from about 100,000 Da to about 5,000,000 Da, from about 500,000 Da to about 4,000,000 Da or from about 1,000,000 Da to about 3,000,000 Da. The weight average molecular weight is calculated by calculating the sum of the product of the weight average molecular weight of each nonwoven web forming material raw material and their corresponding relative weight percentages according to the total weight of the polymer present in the long filaments.
[0110] The polymer may be polyvinyl alcohol having a weight average molecular weight of about 10,000 Da to about 250,000 Da, in another embodiment about 15,000 Da to about 200,000 Da, and in another embodiment about 20,000 Da to about 150,000 Da.
[0111] The polyvinyl alcohol may have a degree of hydrolysis of about 60% to 100%, about 65% to about 85%, less than 85%, about 70% to about 80%, or about 65% to about 95%.
[0112] The polymer may be selected from the group consisting of alginate, starch-based polymers, natural starch, modified starch, and combinations thereof, having a weight average molecular weight of about 1,000,000 Da to about 6,000,000 Da, about 1,500,000 Da to about 5,000,000 Da, or about 2,000,000 Da to about 4,000,000 Da.
[0113] The polymer may be selected from the group consisting of polyvinyl alcohol, pullulan, pectin, corn starch, modified corn starch, hydroxypropyl methylcellulose, and combinations thereof.
[0114] The fiber composition may comprise from about 0.1% to about 50%, from about 5% to about 40%, from about 15% to about 35%, from about 20% to about 30%, or from about 15% to about 30% polymer, by weight of the fiber composition.
[0115] The non-fibrous composition may comprise from about 0.1% to about 50%, from about 5% to about 40%, from about 15% to about 35%, from about 20% to about 30%, or from about 15% to about 30% of a polymer, by weight of the non-fibrous composition or oral care composition.
[0116] Plasticizers
[0117] The oral care composition may include a plasticizer. Non-limiting examples of plasticizers may include polyols, polycarboxylic acids, polyesters, other suitable plasticizers, and combinations thereof.
[0118] Non-limiting examples of polycarboxylic acids may include citric acid, succinic acid, and combinations thereof.
[0119] Non-limiting examples of the polyester may include triacetin, diethyl phthalate, triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, and combinations thereof.
[0120] Non-limiting examples of other suitable plasticizers include, but are not limited to, alkyl and allyl phthalates; lactates (e.g., sodium, ammonium and potassium salts); lactic acid; soluble collagen; modified proteins; monosodium L-glutamate; proteins and amino acids, such as glutamic acid, aspartic acid and lysine; hydrogenated starch hydrolysates; other low molecular weight esters (e.g., esters of C2-C10 alcohols and acids); and any other plasticizers known to those skilled in the food, dietary supplement and pharmaceutical industries; and combinations thereof.
[0121] Polyols
[0122] The oral care composition may include a polyol. The fiber composition or the non-fiber composition may include a polyol. The fiber web forming material may include a polyol. The foam forming material may include a polyol. A polyol is an organic compound having more than one hydroxyl functional group. The polyol may include a sugar alcohol, a non-reducing sugar, a monosaccharide, a disaccharide, a polysaccharide and / or a combination thereof.
[0123] Sugar alcohols are a type of polyols that can be identified by having the formula (CHOH) n H2 is obtained by hydrogenation of a sugar compound, preferably wherein n = 2 to 6. Suitable sugar alcohols include ethylene glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, heptyl alcohol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol and / or polyglucitol.
[0124] Non-reducing sugars are a class of sugars that do not form any compounds containing aldehyde functional groups. Non-reducing sugars are stable in water and do not react with weak oxidants to produce sugar alcohols.
[0125] Non-limiting examples of monosaccharides may include glucose, fructose, and combinations thereof.
[0126] Non-limiting examples of disaccharides can include sucrose, maltose, lactose, high fructose corn syrup solids, trehalose, cellobiose, gentiobiose, isomaltose, kojibiose, laminaribiose, mannobiose, melibiose, nigerose, rutinose, xylobiose, lactulose, and combinations thereof.
[0127] Non-limiting examples of triose can include glyceraldehyde, dihydroxyacetone, and combinations thereof.
[0128] Non-limiting examples of tetrose can include erythrose, threose, erythrulose, and combinations thereof.
[0129] Non-limiting examples of pentoses can include arabinose, lyxose, ribose, xylose, ribulose, xylulose, and combinations thereof.
[0130] Non-limiting examples of hexoses may include allose, altrose, galactose, glucose, gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose, and combinations thereof.
[0131] Non-limiting examples of heptose may include mannoheptulose, sedoheptulose, and combinations thereof.
[0132] Non-limiting examples of octoses may include octotoluene, 2-keto-3-deoxy-mannose-octanoate, and combinations thereof. Non-limiting examples of nonoses may include sialoses.
[0133] The oral care composition may comprise from about 0.01% to about 50%, from about 0.1% to about 50%, from about 1% to about 40%, from about 2% to about 25%, from about 5% to about 15%, or from about 5% to about 10%, by weight of the oral care composition, of a polyol.
[0134] water
[0135] The oral care composition may contain about 0.01% to about 50% water by weight of the oral care composition. The oral care composition may contain about 0.01% to about 30%, about 0.1% to about 25%, about 0.5% to about 15%, or about 1% to about 15% water by weight of the composition. Water may be added directly to the formulation and / or may enter the composition by including other ingredients. Preferably, the water is USP water. Alternatively, the oral care composition may contain less than about 5%, less than about 1%, less than about 0.5%, or less than about 0.01% water by weight of the overall composition. The oral care composition may not contain added water except for the minimum amount of water in the commercial product incorporated into the oral care composition or the water incorporated under ambient conditions.
[0136] Abrasive
[0137] The oral care composition may contain from about 0.5% to about 75% abrasive by weight of the oral care composition. The oral care composition may contain from about 5% to about 60%, from about 10% to about 50%, from about 15% to about 55%, or a combination thereof, by weight of the composition. The abrasive may be a calcium-containing abrasive, a silica abrasive, a carbonate abrasive, a phosphate abrasive, an aluminum oxide abrasive, other suitable abrasives, and / or a combination thereof. Some abrasives may fall into several descriptive categories, such as, for example, calcium carbonate, which is both a calcium-containing abrasive and a carbonate abrasive.
[0138] The calcium-containing abrasive may include calcium carbonate, dicalcium phosphate, tricalcium phosphate, calcium orthophosphate, calcium metaphosphate, calcium polyphosphate, calcium hydroxyapatite, and combinations thereof.
[0139] The calcium-containing abrasive may include calcium carbonate.The calcium-containing abrasive may be selected from the group consisting of finely ground natural chalk, ground calcium carbonate, precipitated calcium carbonate, and combinations thereof.
[0140] The carbonate abrasive may include sodium carbonate, sodium bicarbonate, calcium carbonate, strontium carbonate, and / or combinations thereof.
[0141] The phosphate abrasive may include calcium phosphate, sodium hexametaphosphate, dicalcium phosphate, tricalcium phosphate, calcium orthophosphate, calcium metaphosphate, calcium polyphosphate, polyphosphate, pyrophosphate, and / or combinations thereof.
[0142] The silica abrasive may include fused silica, fumed silica, precipitated silica, silica hydrate, and / or combinations thereof.
[0143] The alumina abrasive may include polycrystalline alumina, calcined alumina, fused alumina, mineralized alumina, hydrated alumina, and / or combinations thereof.
[0144] Other suitable abrasives include diatomaceous earth, barium sulfate, wollastonite, perlite, polymethyl methacrylate particles, and their combinations.
[0145] The abrasive may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fibrous composition.
[0146] Fluoride ion source
[0147] The oral care composition may comprise fluoride, such as provided by a fluoride ion source. According to Table A, the unit dose oral care composition comprises a non-inferior dose of fluoride to provide a non-inferior dose of fluoride relative to a control (eg, USP reference paste).
[0148] The unit dose oral care composition may include a suitable amount of fluoride to provide a non-inferior dose. Suitable amounts include greater than 850 ppm, greater than 1000 ppm, greater than 1150 ppm, greater than 1450 ppm, greater than 2000 ppm, or greater than 3000 ppm of fluoride ions and / or fluoride ions. Other suitable amounts of fluoride include greater than 1000 ppm to about 7500 ppm, greater than 1150 ppm to about 7500 ppm, greater than 2000 ppm to about 7500 ppm, or greater than 3000 ppm to about 7500 ppm of fluoride ions and / or fluoride ions.
[0149] The fluoride ion source may be present in an amount sufficient to give a suitable fluoride ion concentration in the composition according to local laws and regulations (e.g., FDA's anti-caries monograph). The oral care composition may contain from about 0.0025% to about 20%, from about 0.0025% to about 10%, from about 0.01% to about 5%, or from about 0.0025% to about 2% of a fluoride ion source by weight of the oral care composition.
[0150] The amount of fluoride ion source is suitable to obtain a theoretical fluoride concentration of about 200 ppm to about 10000 ppm, about 200 ppm to about 4000 ppm, about 800 ppm to about 1500 ppm, or about 1100 ppm to about 1400 ppm as normalized to a unit dose of the oral care composition by addition of water.
[0151] The fluoride ion source may include examples of substances suitable for generating fluoride ions disclosed in US Pat. Nos. 3,535,421 and 3,678,154. The fluoride ion source may include stannous fluoride, sodium fluoride, potassium fluoride, amine fluoride, sodium monofluorophosphate, zinc fluoride, and / or combinations thereof.
[0152] The fluoride ion source and the metal ion source can be the same compound, such as, for example, stannous fluoride, which can generate tin ions and fluoride ions. In addition, the fluoride ion source and the tin ion source can be separate compounds, such as when the metal ion source is stannous chloride and the fluoride ion source is sodium monofluorophosphate or sodium fluoride.
[0153] The fluoride ion source may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fibrous composition.The fluoride ion source may be incorporated into a solid tablet composition or a portion thereof.
[0154] Metal ion source
[0155] Oral care compositions can include metals, such as provided by metal ion sources. Suitable metal ion sources include stannous ion sources, zinc ion sources, copper ion sources, silver ion sources, magnesium ion sources, iron ion sources, sodium ion sources, and manganese (Mn) ion sources and / or combinations thereof. The metal ion source can be a soluble or sparingly soluble stannous, zinc or copper compound with an inorganic counter ion or an organic counter ion. Examples include fluorides, chlorides, fluorochlorides, acetates, hexafluorozirconates, sulfates, tartrates, gluconates, citrates, malates, glycinates, pyrophosphates, metaphosphates, oxalates, phosphates, carbonates and oxides of stannous, zinc and copper.
[0156] Stannous ions, zinc ions and copper ions are derived from metal ion sources and can be present in multiphase oral care compositions in effective amounts to provide oral care benefits or other beneficial effects. It has been found that stannous ions, zinc ions and copper ions help reduce gingivitis, dental plaque, allergies, and help improve breath freshening benefits. An effective amount is defined as at least about 500ppm to about 20,000ppm, preferably about 2,000ppm to about 15,000ppm of metal ions in the total composition. More preferably, the metal ions are present in an amount of about 3,000ppm to about 13,000ppm and even more preferably about 5,000ppm to about 10,000ppm. This is the total amount of metal ions (stannous, zinc, copper and mixtures thereof) present in the composition for delivery to the tooth surface.
[0157] Other metal ion sources may include minerals and / or calcium-containing compounds that may result in remineralization, such as, for example, sodium iodide, potassium iodide, calcium chloride, calcium lactate, calcium phosphate, hydroxyapatite, fluoroapatite, amorphous calcium phosphate, crystalline calcium phosphate, sodium bicarbonate, sodium carbonate, calcium carbonate, oxalic acid, dipotassium oxalate, monopotassium sodium hydrogen oxalate, casein phosphopeptides, and / or casein phosphopeptide-coated hydroxyapatite.
[0158] The metal ion source may include a metal salt suitable for generating metal ions in the oral cavity. Suitable metal salts include silver (Ag) salts, magnesium (Mg) salts, iron (Fe) salts, sodium (Na) salts and manganese (Mn) salts, or combinations thereof. Preferred salts include, but are not limited to, gluconates, chlorates, citrates, chlorides, fluorides and nitrates, or combinations thereof.
[0159] The oral care composition can include at least about 0.005%, about 0.005% to about 10%, about 0.01% to about 5%, about 0.01% to about 2%, or about 0.1% to about 1% of a metal ion source, based on the weight of the oral care composition. The metal ion source can be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0160] Tin ion source
[0161] Tin ions (such as stannous ions) are used in oral care compositions to deliver beneficial effects, such as enamel care and caries protection. Suitable tin ion sources include stannous chloride, stannous fluoride, stannous bromide, stannous iodide, stannous acetate, stannous gluconate, stannous oxalate, stannous sulfate, stannous lactate, stannous tartrate, stannous carbonate, stannous chloride, stannous fluoride, stannous iodide, stannous citrate, stannous nitrate, stannous peptides, stannous proteins and stannous phosphate and combinations thereof. Preferably, the ion source is stannous fluoride, stannous chloride and combinations thereof.
[0162] The oral care composition according to an embodiment of the present invention may include a tin ion source in an amount ranging from about 0.01% to about 5%, from about 0.05% to about 4%, from about 0.01% to about 10%, or from about 0.075% to about 3%. The tin ion source may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0163] Zinc ion source
[0164] The oral care composition may include about 0.01% to about 5%, about 0.2% to about 2% or about 0.01% to about 10% of a zinc ion source by weight of the oral care composition. The zinc ion source may be selected from the group consisting of zinc citrate, zinc chloride, zinc sulfate, zinc gluconate, zinc lactate, zinc phosphate, zinc oxide, zinc arginine, zinc fluoride, zinc iodide, zinc carbonate and a combination thereof. More preferably, the zinc ion source is selected from zinc citrate, zinc gluconate, zinc lactate and a combination thereof. Insoluble or slightly soluble zinc compounds (such as zinc oxide or zinc carbonate) may be used as zinc ion sources. The zinc source may be a soluble zinc source, such as zinc chloride or zinc sulfate. In addition, the zinc ion source may be those in which zinc has been combined with a suitable chelating agent in the form of a salt or other complex, such as zinc citrate, zinc gluconate, zinc lactate and zinc glycinate. Other examples of zinc ion sources are zinc citrate, zinc gluconate, zinc lactate and a mixture thereof.
[0165] When both insoluble and soluble zinc compounds are present in the zinc ion source, the soluble zinc compound may be present in an amount of at least about 50% by weight of the total zinc ion source. The oral care composition according to an embodiment of the present invention may also optionally include other antibacterial agents, which are preferably present in an amount of about 0.035% or more, about 0.05% to about 2%, about 0.1% to about 1% by weight of the oral care composition. Examples of these other antibacterial agents may include non-cationic antibacterial agents, such as, for example, halogenated diphenyl ethers, phenolic compounds (including phenol and its homologues), monoalkyl halogenated phenols and polyalkyl halogenated phenols and aromatic halogenated phenols, resorcinol and its derivatives, xylitol, bisphenol compounds and halogenated salicylanilides, benzoates and halogenated carbanilides. Other useful antibacterial agents are enzymes, including endoglycosidases, papain, glucanase, mutant enzymes, and combinations thereof. In another example, other antimicrobial agents may include triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol).
[0166] The zinc ion source may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0167] Copper ion source
[0168] The oral care composition may contain from about 0.01% to about 5%, from about 0.2% to about 2%, or from about 0.01% to about 10% of a copper ion source by weight of the oral care composition. The copper ion source may be selected from the group consisting of copper gluconate, copper citrate, copper fluoride, copper iodide, copper bromide, copper peptides, copper sulfate, copper argininate, copper carbonate, and combinations thereof. The copper salt may be in any possible oxidation state, including, for example, copper (I) or copper (II) salts. The copper ion source may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0169] Calcium ion source
[0170] The oral care composition may include a source of calcium ions. The source of calcium ions may include a calcium salt such as, for example, calcium chloride and / or a calcium-containing abrasive, as described herein.
[0171] The calcium compound may include any suitable soluble calcium salt, such as, for example, calcium chloride, calcium carbonate, calcium bicarbonate, calcium hydroxide, calcium lactate, calcium citrate, calcium phosphate, and combinations thereof.
[0172] The oral care composition may comprise from about 0.01% to about 10%, from about 1% to about 50%, from about 10% to about 50%, or from about 1% to about 30%, by weight of the oral care composition, of a calcium ion source.
[0173] Surfactants
[0174] The oral care composition may include one or more surfactants. The fiber composition may include one or more surfactants. The non-fiber composition may include one or more surfactants. The one or more surfactants may be selected from anionic surfactants, nonionic surfactants, amphoteric surfactants, zwitterionic surfactants, cationic surfactants or combinations thereof.
[0175] The oral care composition may contain one or more surfactants at a level of from about 0.01% to about 20%, from about 1% to about 15%, from about 0.1% to about 15%, from about 5% to about 15%, or greater than about 5%, by weight of the composition.
[0176] Suitable anionic surfactants include, for example, water-soluble salts of alkyl sulfates having 8 to 20 carbon atoms in the alkyl group and water-soluble salts of sulfonated monoglycerides of fatty acids having 8 to 20 carbon atoms. Examples of such anionic surfactants are sodium lauryl sulfate (SLS) and sodium coconut monoglyceride sulfonates. Other suitable anionic surfactants include sarcosinates (such as sodium lauroyl sarcosinate), taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecylbenzene sulfonate. Combinations of anionic surfactants may also be used.
[0177] Another class of suitable anionic surfactants are alkyl phosphates. These surface active organophosphate agents can have a strong affinity for enamel surfaces and have sufficient surface binding propensity to desorb surface membrane proteins and remain attached to the enamel surface. Suitable examples of organophosphate compounds include monoesters, diesters, triesters represented by the following general structure:
[0178]
[0179] Wherein Z1, Z2 or Z3 may be the same or different, at least one of which is an organic moiety. Z1, Z2 or Z3 may be selected from a linear or branched alkyl group or alkenyl group of 1 to 22 carbon atoms, optionally substituted by: one or more phosphate groups; alkoxylated alkyl groups or alkenyl groups, (poly) sugar groups, polyol groups or polyether groups.
[0180] Some other reagents include alkyl or alkenyl phosphates represented by the following structures:
[0181]
[0182] wherein R1 represents a straight or branched alkyl or alkenyl group having 6 to 22 carbon atoms, optionally substituted with one or more phosphate groups; n and m are individually and separately 2 to 4, and a and b are individually and separately 0 to 20; Z and Z may be the same or different, each representing hydrogen, an alkali metal, ammonium, a protonated alkylamine or a protonated functional alkylamine such as an alkanolamine or an R—(OCH2)(OCH)- group. Examples of suitable agents include alkyl phosphates and alkyl (poly) alkoxy phosphates such as lauryl phosphate; PPGS ceteareth-10 phosphate; laureth-1 phosphate; laureth-3 phosphate; laureth-9 phosphate; trilaureth-4 phosphate; C 12-18 PEG 9 Phosphate: and sodium laureth-10 phosphate. The alkyl phosphates may be polymeric. Examples of polymeric alkyl phosphates include those containing repeating alkoxy groups as polymeric moieties, specifically those containing 3 or more ethoxy groups, propoxy groups, isopropoxy groups, or butoxy groups.
[0183] Other suitable surfactants are sarcosinates, isethionates and taurates, especially the alkali metal or ammonium salts thereof. Examples include: lauroyl sarcosinate, myristoyl sarcosinate, palmitoyl sarcosinate, stearoyl sarcosinate, oleoyl sarcosinate or combinations thereof.
[0184] Zwitterionic surfactants or amphoteric surfactants that can be used herein include derivatives of aliphatic quaternary ammonium compounds, phosphonium compounds and sulfonium compounds, wherein the aliphatic group may be linear or branched, and one of the aliphatic substituents contains 8 to 18 carbon atoms, and one of the aliphatic substituents contains an anionic water-solubilizing group, for example, carboxyl, sulfonate, sulfate, phosphate or phosphonate. Suitable betaine surfactants are disclosed in U.S. Pat. No. 5,180,577. Typical alkyl dimethyl betaines include decyl betaine or 2-(N-decyl-N,N-dimethylamine) acetate, coconut betaine or 2-(N-cocoyl-N,N-dimethylamine) acetate, tetradecyl betaine, palmityl betaine, lauryl betaine, hexadecyl betaine, hexadecyl betaine, stearyl betaine, etc. Amidobetaines are exemplified by cocamidoethyl betaine, cocamidopropyl betaine (CADB) and lauramidopropyl betaine.
[0185] Cationic surfactants useful in embodiments of the present invention include, for example, quaternary ammonium compound derivatives having a long alkyl chain containing 8 to 18 carbon atoms, such as lauryltrimethylammonium chloride; cetylpyridinium chloride; hexadecyltrimethylammonium bromide; hexadecylpyridinium fluoride, or combinations thereof.
[0186] Nonionic surfactants useful in the compositions of embodiments of the present invention include, for example, compounds formed by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkyl aromatic in nature. Examples of suitable nonionic surfactants may include (i.e., poloxamers), polyethylene oxide condensates of alkylphenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylenediamine, ethylene oxide condensates of fatty alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides, and combinations of these substances.
[0187] One or more surfactants may also include one or more natural surfactants. Natural surfactants may include surfactants derived from natural products and / or minimally processed or unprocessed surfactants. Natural surfactants may include: hydrogenated, non-hydrogenated or partially hydrogenated vegetable oils, vegetable oils, passion fruit oil, candelilla wax, coconut oil base caprylate, caprate, dioctyl ether, lauryl alcohol, myristate tetradecyl ester, dioctyl ether, caprylic acid, caprylate, caprylate, caprylate, undecane, tridecane, decyl oleate, decyl oleate, palmitic acid hexadecyl ester, stearic acid, palmitic acid, stearyl glyceride, hydrogenated, non-hydrogenated or partially hydrogenated vegetable glycerides, polyglyceryl-2 dipolyhydroxystearate, hexadecanol / octadecyl alcohol, sucrose polystearate, glycerol, stearyl alcohol, hydrolyzed, partially hydrolyzed The present invention can be used to prepare the present invention, for example, vegetable protein, hydrolyzed, partially hydrolyzed or unhydrolyzed wheat protein hydrolyzate, polyglyceryl-3 diisostearate, olein, myristyl alcohol, cetyl alcohol, sodium cetearyl sulfate, cetearyl alcohol, lauric acid glyceryl, capric triglyceride, coconut oil glyceride, lecithin, dicaprylyl ether, xanthan gum, sodium coconut sulfate, ammonium lauryl sulfate, sodium coconut sulfate, sodium coconut glutamate, polyalkyl glucoside (such as decyl glucoside, cetearyl glucoside), cetearyl polyglucoside, coconut oil glucoside and lauryl glucoside and / or their combination. The natural surfactant can include any of the natural ingredients sold by BASF, such as, for example and / or a combination thereof.
[0188] The surfactant may be formed within the fiber composition, added to the surface of the fiber composition, and / or included in the non-fiber composition. The surfactant formed within the fiber composition may be present at a level of about 10% to about 50%, about 20% to about 40%, about 25% to about 40%, or about 30% to about 40%, based on the weight of the fiber composition.
[0189] The oral care composition may comprise one or more surfactants.The oral care composition may comprise anionic surfactants, cationic surfactants, nonionic surfactants and / or zwitterionic surfactants.
[0190] The oral care composition may comprise from about 0.1% to about 10%, from about 0.1% to about 8%, from about 5% to about 8%, from about 4% to about 9%, or from about 3% to about 10%, by weight of the composition, of an anionic, cationic and / or nonionic surfactant.
[0191] The oral care composition may contain from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.1% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, or from about 0.1% to about 0.2%, by weight of the composition, of a zwitterionic surfactant.
[0192] PEG
[0193] The oral care composition may include polyethylene glycol (PEG) having different weight percentages of the composition and various average molecular weight ranges. The composition may have about 0.1% to about 40%, about 1% to about 35%, about 5% to about 30%, about 15% to about 25%, about 1% to about 40%, about 10% to about 30%, about 15% to about 20%, about 0.1% to about 30%, or about 15% to about 30% PEG by weight of the composition. The PEG may have an average molecular weight range of about 100 Daltons to about 1600 Daltons, about 200 to about 1000, about 400 to about 800, about 500 to about 700 Daltons, or a combination thereof. PEG is a water-soluble linear polymer formed by the addition reaction of ethylene oxide with an ethylene glycol equivalent having the general formula: H-(OCH2CH2) n -OH. One supplier of PEG is CARBOWAX TM Brand of Dow Chemical Company.
[0194] PEG can be formed within the fiber composition, added to the surface of the fiber composition, or included in the non-fibrous composition. The PEG included in the non-fibrous composition can be present at a level of about 10% to about 50%, about 15% to about 40%, about 5% to about 35%, or about 15% to about 30% by weight of the non-fibrous composition. When used as a solvent for the non-fibrous composition, the PEG can be anhydrous to prevent reactivity between components dispersed or dissolved in the PEG.
[0195] Polyphosphate
[0196] The oral care composition may include a polyphosphate source. The polyphosphate source may include one or more polyphosphate molecules. Polyphosphates are a class of substances obtained by dehydration and condensation of orthophosphates to form linear and cyclic polyphosphates of varying chain lengths. Therefore, polyphosphate molecules are typically identified by the average number (n) of polyphosphate molecules, as described below. Although some cyclic derivatives may exist, polyphosphates are generally considered to consist of two or more phosphate molecules arranged primarily in a linear configuration.
[0197] Preferred polyphosphates are those having an average of two or more phosphate groups so that surface adsorption at effective concentrations produces sufficient unbound phosphate functionality, which enhances the anionic surface charge and the hydrophilic character of the surface. Preferred are linear polyphosphates having the formula: XO(XPO3) n X, wherein X is sodium, potassium, ammonium or any other alkali metal cation, and n averages from about 2 to about 21. The polyphosphate source may also include alkaline earth metal polyphosphates, and specifically calcium polyphosphate salts, such as calcium pyrophosphate, due to the ability to separate calcium ions from other reactive components, such as a fluoride ion source.
[0198] Some examples of suitable polyphosphate molecules include, for example, pyrophosphate (n=2), tripolyphosphate (n=3), tetrapolyphosphate (n=4), sodium polyphosphate (n=6), hexapolyphosphate (n=13), benzene polyphosphate (n=14), hexametaphosphate (n=21), also known as Glass H. Polyphosphates may include those polyphosphate compounds produced by FMC Corporation, ICL Performance Products, and / or Astaris.
[0199] The oral care composition may comprise from about 0.01% to about 15%, from about 0.1% to about 10%, from about 0.5% to about 5%, from about 1% to about 20%, or about 10% or less, by weight of the oral care composition, of a polyphosphate source.
[0200] Extension additives
[0201] The oral care composition may include an extension aid. Non-limiting examples of extension aids may include polymers, other extension aids, and combinations thereof.
[0202] The extension aid may have a weight average molecular weight of at least about 500,000 Da. The weight average molecular weight of the extension aid may be from about 500,000 to about 25,000,000, from about 800,000 to about 22,000,000, from about 1,000,000 to about 20,000,000, or from about 2,000,000 to about 15,000,000. High molecular weight extension aids are preferred in some embodiments due to their ability to increase extension melt viscosity and reduce melt fracture.
[0203] When used for melt-blowing, an effective amount of an extension aid can be added to the composition according to an embodiment of the present invention to visually reduce the melt fracture and capillary breakage of the filaments during the spinning process, so that substantially continuous filaments with relatively consistent diameters can be melt-spun. Regardless of the method for preparing the filaments, when used, the extension aid can be present in an amount of about 0.001% to about 10% by weight based on dry filaments, about 0.005% to about 5% by weight based on dry filaments, about 0.01% to about 1% by weight based on dry filaments, or about 0.05% to about 0.5% by weight based on dry filaments.
[0204] Non-limiting examples of polymers that may be used as extension aids may optionally include alginates, carrageenan, pectin, chitin, guar gum, xanthan gum, agar, gum arabic, gum karaya, gum tragacanth, locust bean gum, alkyl cellulose, hydroxyalkyl cellulose, carboxyalkyl cellulose, and mixtures thereof.
[0205] Non-limiting examples of other extension aids may include hydroxy-modified polyacrylamide, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone, polyethylene vinyl acetate, polyethylene imine, polyamide, polyalkylene oxide including polyethylene oxide, polypropylene oxide, polyethylene propylene oxide and mixtures thereof.
[0206] Beautifier
[0207] The oral care composition may optionally contain one or more aesthetic agents. The one or more aesthetic agents may be selected from the group consisting of flavoring agents, coloring agents, sensates, sweeteners, salivation agents, and combinations thereof. All aesthetic agents may be present in an amount of about 0.001% to about 60% by weight of the oral care composition, about 0.005% to about 50% by weight of the oral care composition, about 0.05% to about 40% by weight of the oral care composition, or about 0.1% to about 35% by weight of the oral care composition.
[0208] The aesthetic agent may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0209] Flavoring
[0210] The oral care composition may optionally include one or more flavoring agents.Non-limiting examples of flavoring agents useful in accordance with embodiments of the present invention may include natural flavoring agents, artificial flavoring agents, artificial extracts, natural extracts, and combinations thereof. Non-limiting examples of flavoring agents may include vanilla, honey, lemon, lemon honey, cherry vanilla, peach, honey ginger, chamomile, cherry, cherry cream, mint, vanilla mint, berry, blackberry, raspberry, peppermint, spearmint, honey peach, acai berry, bilberry, honey bilberry, tropical fruit, dragon fruit, snow fruit, red dried mint, pomegranate, black currant, strawberry, lemon, lime, peach ginger, orange, orange cream, cream popsicle, apricot, fennel, ginger, durian, star fruit, blueberry, fruit wine, lemongrass, chamomile lemongrass, lavender, banana, strawberry banana, grape, blueberry, lemon lime, coffee, espresso, cappuccino, honey, wintergreen mint, bubble gum, sour honey lemon, sour lemon, green apple, boshi berry, cranberry, strawberry rhubarb, persimmon, green tea, black tea, white tea, honey lime, cherry lime, apple, tangerine, grapefruit, kiwi, pear, vanilla extract, ethyl vanillin, wheat Maltol, ethyl maltol, pumpkin, carrot cake, white chocolate raspberry, chocolate, white chocolate, milk chocolate, dark chocolate, chocolate marshmallow, apple pie, cinnamon, hazelnut, almond, cream, crème brûlée, caramel, caramel nut, butter, toffee, caramel toffee, aloe vera, whiskey, rum, cocoa, licorice, pineapple, guava, melon, watermelon, elderberry, mouth freshener, raspberry cream, peach mango, tropical plant, cool berry, lemon ice, nectar, spicy nectar, tropical mango, apple butter, peanut butter, tangerine, tangerine lime, marshmallow, cotton candy, apple juice, orange chocolate, adipic acid, citral, denatonium benzoate, ethyl acetate, ethyl lactate, ethyl maltol, ethylcellulose, fumaric acid, leucine, malic acid, menthol, methionine, monosodium glutamate, sodium acetate, sodium lactate, tartaric acid, thymol, and combinations thereof.
[0211] The flavoring agent can be protected in the encapsulate or as a flavoring agent crystal. Once the encapsulated flavoring agent reaches the oral cavity, the encapsulated flavoring agent can have a controlled or delayed release. The encapsulate may include a shell and a core. The flavoring agent may be in the core of the encapsulate. The flavoring agent may be encapsulated by any suitable means (such as spray drying or extrusion). The encapsulated flavoring agent may be added to the surface of the fiber composition, formed in the fiber composition, or included in a non-fiber composition.
[0212] The flavoring agents may be present in an amount from about 0.05% to about 25% by weight of the oral care composition, from about 0.01% to about 15% by weight of the oral care composition, from about 0.2% to about 10% by weight of the oral care composition, or from about 0.1% to about 5% by weight of the oral care composition.
[0213] The flavoring agent may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0214] Colorants
[0215] The oral care composition may optionally include one or more colorants. The colorant may provide a visual signal when the oral care composition is exposed to the conditions of intended use. Non-limiting examples of colorants that can be used in embodiments of the present invention include FD&C Blue #1, FD&C Blue #2, D&C Blue #4, D&C Blue #9, FD&C Green #3, D&C Green #5, D&C Green #6, D&C Green #8, D&C Orange #4, D&C Orange #5, D&C Orange #10, D&C Orange #11, FD&C Red #3, FD&C Red #4, D&C Red #6, D&C Red #7, D&C Red #17, D&C Red #18, D&C Orange #20, D&C Orange #21, D&C Orange #22, D&C Orange #23, D&C Orange #24, D&C Orange #25, D&C Orange #26, D&C Orange #27, D&C Orange #28, D&C Orange #29, D&C Orange #30, D&C Orange #31, D&C Orange #32, D&C Orange #33, D&C Red #34, D&C Red #35, D&C Red #36, D&C Red #37, D&C Red #38, D&C Orange #39, D&C Orange #40, D&C Orange #41, D&C Orange #42, D&C Orange #43, D&C Orange #44, D&C Orange #45, D&C Orange #46, D&C Red #47, D&C Red #48, D&C Red #49, D&C Red #50, D&C Orange #51, D&C Orange #52, D&C Orange #53, D&C Orange #5 The colorant may be present in an amount of about 0.05% to about 2% by weight of the oral care composition, about 0.01% to about 2% by weight of the oral care composition, or about 0.02% to about 1.5% by weight of the oral care composition.
[0216] The colorant may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0217] Sensate
[0218] The oral care composition may optionally include one or more sensates. Non-limiting examples of sensates may include cooling sensates, warming sensates, tingling sensates, and combinations thereof. Sensates may be used to deliver a signal to the user.
[0219] Non-limiting examples of cooling agents may include WS-23 (2-isopropyl-N,2,3-trimethylbutanamide), WS-3 (N-ethyl p-menthane-3-carboxamide), WS-30 (1-glyceryl p-menthane-3-carboxylate), WS-4 (ethylene glycol p-menthane-3-carboxylate), WS-14 (N-tert-butyl p-menthane-3-carboxamide), WS-12 (N-(4-ethoxyphenyl) p-menthane-3-carboxamide), WS-5 (ethyl-3-(p-menthane-3-carboxamido) acetate, menthone glycerol ketal (produced by Haarmann & Reimer as MGA), (-)-menthyl lactate (sold by Haarmann & Reimer as ML), (-)-menthoxypropane-1,2-diol (sold by Takasago International as Coolant Agent 10), 3-(l-menthoxy)propane-1,2-diol, 3-(l-menthoxy)-2-methylpropane-1,2-diol, (-)-isopulegol sold by Takasago International under the trade name "Coolant Agent 10". For Sale, cis- and trans-p-menthane-3,8-diol (PMD38) - Takasago International, (Menthyl pyrrolidonecarboxylate), (1R,3R,4S)-3-menthyl-3,6-dioxaheptanoate-Firmenich, (1R,2S,5R)-3-menthyl methoxyacetate-Firmenich, (1R,2S,5R)-3-menthyl-3,6,9-trioxadecanoate-Firmenich, (1R,2S,5R)-11-hydroxy-3,6,9-trioxadecanoate-Firmenich, (1R,2S,5R)-3-menthyl (2-hydroxyethoxy) acetate-Firmenich, Cubebol-Firmenich, Ice is also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-one, 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone, Frescolat ML-menthyl lactate, Frescolat MGA-menthone glycerol acetal, peppermint oil, Givaudan 180, L-monomenthyl succinate, L-monomenthyl glutarate, 3-l-menthoxypropane-1,2-diol-(Coolact 10), 2-l-menthoxyethanol (Cooltact 5), TK10Coolact (3-l-menthoxypropane-1,2-diol), Evercool 180 (N-phenylacetonitrile-menthane carboxamide) and combinations thereof. The cooling sensate can be present in an amount of about 0.005% to about 10% by weight of the oral care composition, about 0.05% to about 7% by weight of the oral care composition, or about 0.01% to about 5% by weight of the oral care composition.
[0220] Non-limiting examples of warming sensates can include TK 1000, TK 1MM, Heatenol-Sensient flavors, Optaheat-Symrise flavors, cinnamon, polyethylene glycol, chili pepper, capsaicin, curry, FSI flavors, isobutyl alcohol, ethanol, glycerol, niacinamide 60162807, Hotact VEE, Hotact 1MM, piperine, optaheat 295 832, optaheat204 656, optaheat200 349, and combinations thereof. The warming sensate can be present in an amount of about 0.005% to about 60% by weight based on dry filaments, about 0.05% to about 50% by weight based on dry filaments, or about 0.01% to about 40% by weight based on dry filaments. The warming sensate may be present in an amount from about 0.005% to about 10% by weight of the oral care composition, from about 0.05% to about 7% by weight of the oral care composition, or from about 0.01% to about 5% by weight of the oral care composition.
[0221] Non-limiting examples of tingling sensates can include Zanthoxylum bungeanum, hydroxy alpha sanshool, citric acid, spiky nut extract, spilanthol, and combinations thereof. The tingling sensate can be present in an amount of about 0.005% to about 10% by weight based on the dry filament or by weight of the oral care composition, about 0.01% to about 7% by weight based on the dry filament or by weight of the oral care composition, or about 0.015% to about 6% by weight based on the dry filament or by weight of the oral care composition.
[0222] Sensates may be formed within the fiber composition, added to the surface of the fiber composition, or included in non-fibrous compositions.
[0223] Sweeteners
[0224] Oral care compositions may optionally include one or more sweeteners. Sweeteners may be natural or artificial. Non-limiting examples of sweeteners may include nutritional sweeteners, sugar alcohols, synthetic sweeteners, high-intensity natural sweeteners, and combinations thereof. All sweeteners may be present in an amount of about 0.05% to about 60% by weight of the oral care composition, about 0.1% to about 50% by weight of the oral care composition, or about 1% to about 10% by weight of the oral care composition.
[0225] Non-limiting examples of nutritive sweeteners may include sucrose, dextrose, glucose, fructose, lactose, tagatose, maltose, trehalose, and combinations thereof. Nutritive sweeteners may be present in an amount of about 0.1% to about 60% by weight of the oral care composition, about 1% to about 50% by weight of the oral care composition, or about 0.1% to about 10% by weight of the oral care composition.
[0226] Non-limiting examples of sugar alcohols can include xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, and combinations thereof. Sugar alcohols can be present in an amount of about 0.1% to about 60% by weight of the oral care composition, about 0.11% to about 50% by weight of the oral care composition, or about 0.1% to about 10% by weight of the oral care composition.
[0227] Non-limiting examples of synthetic sweeteners can include aspartame, acesulfame potassium, alitame, saccharin sodium, sucralose, neotame, cyclamates, and combinations thereof. The synthetic sweetener can be present in an amount of about 0.05% to about 10% by weight of the oral care composition, about 0.1% to about 5% by weight of the oral care composition, or about 0.25% to about 4% by weight of the oral care composition.
[0228] Non-limiting examples of high intensity natural sweeteners can include neohesperidin dihydrochalcone, stevioside, rebaudioside A, rebaudioside C, dulcoside, monoammonium glycyrrhizinate, african sweeteners, and combinations thereof. High intensity natural sweeteners can be present in an amount of about 0.05% to about 10% by weight of the oral care composition, about 0.1% to about 5% by weight of the oral care composition, or about 0.25% to about 4% by weight of the oral care composition.
[0229] The sweetener may be formed within the nonwoven web, added to the surface of the nonwoven web, or included in the nonwoven composition.
[0230] Salivation Agents
[0231] The oral care composition may optionally include one or more salivation agents. Non-limiting examples of salivation agents include formula (I):
[0232]
[0233] wherein R1 represents a C1-C2 n-alkyl group; R2 is a 2-methyl-1-propyl group, and R3 is hydrogen, or R2 and R3 together have the formula –(CH2) n -portions (indicated by dashed lines), where n is 4 or 5, and combinations thereof.
[0234] The salivating agent may include a material wherein R2 is 2-methyl-1-propyl and R3 is hydrogen, or the salivating agent may include a material wherein R1 is a C1 n-alkyl, R2 is 2-methyl-1-propyl and R3 is hydrogen. The salivating agent may include trans-pellitorine, a chemical having a structure according to formula (II):
[0235]
[0236] The salivation agent may include sodium bicarbonate, sodium chloride, trans-pellitorine, pilocarpine, citrate, and combinations thereof. The salivation agent may be present in an amount of about 1% to about 60%, about 1% to about 50%, or about 1% to about 40%, by weight of the oral care composition. Additionally, the salivation agent may be present in an amount of about 0.005% to about 10%, by weight of the oral care composition, ...
[0237] The salivating agent may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fibrous composition.
[0238] Thickener
[0239] The oral care compositions herein may include one or more thickeners. The thickener may be used in an amount of about 0.01% to about 15%, or about 0.1% to about 10%, or about 0.1% to about 5%, by weight of the oral care composition. Non-limiting examples may include those described in US2008 / 0081023 A1, paragraphs 134 to 137, and references cited therein.
[0240] The oral care composition may include a linear sulfated polysaccharide as a thickener. Carrageenan or carrageenan is an example of a linear sulfated polysaccharide. In general, carrageenan can vary based on the degree of sulfation, including: kappa-carrageenan, iota-carrageenan, and lambda-carrageenan. Combinations of carrageenans can be used. The oral care composition may include from about 0.1% to about 3%, from about 0.5% to about 2%, from about 0.6% to about 1.8%, or a combination thereof, by weight of the oral care composition.
[0241] The oral care composition may comprise a silica agent, preferably a thickened silica obtained from a sodium silicate solution by destabilization with an acid to obtain very fine particles. A commercially available example is Silica from Huber Engineered Materials. Brand silica (e.g. 103, 124, 113, 115, 163, 165, 167). The oral care composition may contain from about 0.5% to about 5%, preferably from about 1% to about 4%, alternatively from about 1.5% to about 3.5%, alternatively from about 2% to about 3%, alternatively from about 2% to about 5%, alternatively from about 1% to 3%, alternatively combinations thereof, of a silica agent, based on the weight of the oral care composition.
[0242] The thickener may comprise carboxymethyl cellulose ("CMC"). CMC is prepared from cellulose by treatment with alkali and monochloroacetic acid or its sodium salt. The different commercial types are characterized by viscosity. One commercially available example is Aqualon from Ashland Special Ingredients. TM Brand CMC (e.g., Aqualon TM 7H3SF; Aqualon TM 9M3SF Aqualon TM TM9A; Aqualon TM TM12A). The thickener may comprise from about 0.1% to about 3%, preferably from about 0.5% to about 2%, alternatively from about 0.6% to about 1.8%, alternatively combinations thereof, of CMC by weight of the oral care composition.
[0243] The thickening agent may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fibrous composition.
[0244] Chelating agents
[0245] Oral care compositions according to embodiments of the present invention may optionally contain one or more chelating agents, also referred to as chelating agents. As used herein, the term "chelating agent" refers to a bidentate or multidentate ligand having at least two groups capable of binding metal ions and preferably capable of binding other divalent or multivalent metal ions, and the chelating agent, which is at least part of a chelating agent mixture, is capable of solubilizing tin ions or other optional metal ions in the oral care composition. Groups capable of binding metal ions include carboxyl, hydroxyl and amine groups.
[0246] Suitable chelating agents herein include C2-C6 dicarboxylic acids and tricarboxylic acids, such as succinic acid, malic acid, tartaric acid and citric acid; C3-C6 monocarboxylic acids substituted with hydroxyl groups, such as gluconic acid; picolinic acid; amino acids, such as glycine; their salts and mixtures thereof. Chelating agents may also be polymers or copolymers in which the chelating ligands are on the same or adjacent monomers.
[0247] Preferred chelating agent polymers are polyacids selected from the group consisting of homopolymers of monomers, copolymers of two or more different monomers, and combinations thereof, wherein at least one of the monomer or the two or more different monomers is selected from the group consisting of acrylic acid, methacrylic acid, itaconic acid, maleic acid, glutaconic acid, aconitic acid, citraconic acid, mesaconic acid, fumaric acid, and butyric acid. Particularly preferred are methyl vinyl ether / maleic acid (PVM / MA) copolymers. Other available chelating agents include polyphosphates as described herein.
[0248] Preferred organic acid chelating agents herein include citrate, malate, tartrate, gluconate, succinate, lactate, malonate, maleate and mixtures thereof, whether added in their free acid form or in salt form.
[0249] Oral care compositions according to embodiments of the present invention may have low levels of chelating agents because the metal ions may require less stability if introduced into the fiber composition, the non-fiber composition, or physically separated from other reactive components of the oral care composition, which may be added to a separate fiber web layer or to the non-fiber composition. The oral care composition may have less than about 5%, less than about 1%, less than about 0.5%, less than about 0.1%, less than about 0.01%, or 0% chelating agent by weight of the oral care composition. The chelating agent may be formed within the fiber composition, added to the surface of the fiber composition, or contained in the non-fiber composition.
[0250] Whitening Agents
[0251] The oral care composition may also include about 0.1% to about 10%, about 0.2% to about 5%, about 1% to about 5%, or about 1% to about 15% of a whitening agent, based on the weight of the total oral care composition. The whitening agent may be a compound suitable for whitening at least one tooth in the oral cavity. The whitening agent may include peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates, and combinations thereof. Suitable peroxides include solid peroxides, urea peroxide, calcium peroxide, benzoyl peroxide, sodium peroxide, barium peroxide, inorganic peroxides, hydroperoxides, organic peroxides, and mixtures thereof. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite. Other suitable whitening agents include sodium persulfate, potassium persulfate, Peroxydone complex (polyvinyl pyrrolidone and hydrogen peroxide), 6-phthalimidoperoxycaproic acid, phthalimidoperoxycaproic acid, or mixtures thereof.
[0252] Whitening agents can react with other components of the oral care composition and thus can be separated from the other components using the composition designs described herein.Whitening agents can be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0253] Bioactive substances
[0254] The oral care composition may also contain a bioactive material suitable for tooth remineralization. Suitable bioactive materials include bioactive glass, Novamin TM 、Recaldent TM , hydroxyapatite, amino acids (such as, for example, arginine, citrulline, glycine, lysine or histidine) or combinations thereof. Other suitable bioactive materials include any calcium phosphate compound. Other suitable bioactive materials include compounds comprising a calcium source and a phosphate source.
[0255] Bioactive glasses contain calcium and / or phosphates, which may be present in proportions similar to hydroxyapatite. These glasses can bond to tissue and are biocompatible. Bioactive glasses may contain phosphopeptides, a calcium source, a phosphate source, a silica source, a sodium source, and / or combinations thereof.
[0256] The oral care composition may comprise from about 0.01% to about 20%, from about 0.1% to about 10%, or from about 1% to about 10%, by weight of the oral care composition, of a biologically active material.
[0257] The bioactive material may be formed within the fiber composition, added to the surface of the fiber composition, or included in a non-fiber composition.
[0258] Non-fiber composition
[0259] The components described herein may optionally be present at least in part as a non-fibrous composition. The non-fibrous composition may be between two or more fiber web layers, folded within at least one fiber web layer, rolled within at least one fiber web layer, or wrapped within at least one fiber web layer. At least a portion of the non-fibrous composition may contact the surface of the fiber composition. The non-fibrous composition may be liquid, solid, aqueous, and / or combinations thereof.
[0260] The non-fibrous composition may include oral care actives, aesthetic agents, abrasives, fluoride ion sources, fiber web-forming materials, metal ion sources, polyphosphates, chelating agents, anticalculus agents, thickeners, polymers, surfactants, bioactive materials, and / or combinations thereof.
[0261] The non-fibrous composition may comprise from about 10% to about 90%, from about 20% to about 85%, from about 30% to about 80%, from about 40% to about 75%, from about 50% to about 80%, from about 50% to about 90%, or from about 60% to 80%, by weight of the oral care composition.
[0262] The density of the non-fibrous composition may be about 0.05 g / cm 3 To about 5g / cm 3 , about 0.75g / cm 3 To about 1.9g / cm 3 , about 1g / cm 3 To about 1.75g / cm 3 or about 1.4g / cm 3 To about 1.8g / cm 3 .
[0263] In some embodiments, the non-fiber composition can be wrapped by the fiber composition. In addition, it is important that the fiber composition surrounding the non-fiber composition contacts at its edge, that is, the non-fiber composition does not cover the entire area of the fiber composition. Extending the edge of the fiber composition beyond the non-fiber composition helps to ensure that: when the edge is engaged, they can seal to protect the non-fiber composition and release from the manufacturing die-cutting machine. The unit dose composition may include a continuous edge of the fiber material around the periphery of the unit dose composition, which is not touched or exposed by the non-fiber composition. In one embodiment, if or when the unit dose composition includes the fiber composition and the non-fiber composition, the periphery or edge of the unit dose composition may not contain the non-fiber composition. In the embodiment where the unit dose composition is circular, the maximum size of the non-fiber composition may be less than about 70% of the fiber composition diameter, less than about 75% of the fiber composition diameter, less than about 80% of the fiber composition diameter, less than about 85% of the fiber composition diameter, less than about 90% of the fiber composition diameter, or less than about 95% of the fiber composition diameter. For example, the diameter of the fiber composition can be about 0.6875 inches, and the diameter of the non-fibrous composition can be about 0.65 inches, about 0.625 inches, or about 0.6 inches. As another example, the diameter of the fiber composition can be about 0.75 inches, and the diameter of the non-fibrous composition can be about 0.7125 inches, about 0.675 inches, about 0.6375 inches, about 0.6 inches, about 0.5625 inches, or about 0.525 inches. If or when the unit dose composition comprises a fiber composition and a non-fibrous composition, the fiber composition can extend beyond the periphery of the non-fibrous composition. In various embodiments, the distance from the edge of the unit dose oral care composition to the non-fibrous composition is at least about 0.02 inches, at least about 0.03 inches, at least about 0.04 inches, at least about 0.05 inches, at least about 0.1 inches, or at least about 0.15 inches around the periphery of the non-fibrous composition. For example, if the composition is in the shape of a non-circular polygon, the width of the fiber composition at the edge of the oral care composition without the non-fibrous composition can be at least about 0.02 inches, at least about 0.03 inches, at least about 0.04 inches, at least about 0.05 inches, at least about 0.1 inches, or at least about 0.15 inches wide continuously around the perimeter of the non-fibrous composition.
[0264] Coating composition
[0265] The components described herein may optionally exist at least in part as a coating composition. The coating composition may be applied to a fiber composition, a fiber web, or an oral care composition. The coating composition at least partially covers or covers the outer surface of the fiber composition or the fiber web. The coating composition may cover the outer surface of the oral care composition, thereby placing the coating composition in a suitable position to immediately contact the target surface (e.g., saliva in the mouth) during the release of oral care active substances and / or beautifying agents.
[0266] Coating compositions according to embodiments of the present invention may comprise one or more oral care actives as defined herein.Coating compositions may comprise one or more aesthetic agents as defined herein.
[0267] The fiber composition, fiber web or oral care composition may include one or more oral care active substances, which may be the same or different from the oral care active substances present in the coating composition. The fiber composition, fiber web or oral care composition may include delayed delivery, extended delivery and / or directed delivery oral care active substances, and the coating composition includes immediate delivery oral care active substances. The fiber composition, fiber web or oral care composition may include one or more aesthetic agents, which may be the same or different from the aesthetic agents in the coating composition.
[0268] The coating composition may also be embedded in the fiber composition or fiber web. Thus, when the fiber web is formed using any suitable means, particles of the coating composition may fit within the spaces between the fibers or filaments.
[0269] Releasable components
[0270] Other components in oral care actives, beautifying agents or oral care compositions can be designed to release under suitable triggering conditions. Releasable components can release under the same or different triggering conditions. For example, flavoring agent encapsulates can release under the shear rate associated with the user brushing at least one tooth. Fluoride ion source can release when in contact with water. This can allow oral care actives or beautifying agents to release at a specified time. For example, flavoring agents can release 1 second after brushing teeth, and coloring agents can release after the user brushes teeth for two minutes to indicate that the appropriate brushing time has passed. Beautifying agents or oral care actives can be delivered sequentially or simultaneously with other beautifying agents or oral care actives.
[0271] Graphics
[0272] Graphics can be printed directly on the oral care composition. Suitable graphics include graphics that match flavors, graphics of sports team logos or names, graphics that match instructions for use, such as at a specific time of day, after consuming a certain food or beverage, or the type of brush to be used, marketing materials, colors, designs, logos, graphics depicting fictional and non-fictional characters, graphics associated with consumer benefits, logos, phrases, slogans, motivational quotes, brand materials, company information, ingredient lists, animals or other suitable graphics to directly convey information about the oral care composition. Graphics can be printed on each side of the oral care composition. The graphics on each side of the oral care composition can be the same or different.
[0273] Dissolution time
[0274] Oral care compositions can be described by their dissolution time. Oral care compositions according to embodiments of the present invention dissolve much faster than comparable paste dentifrices. According to the dissolution method as described herein, an oral care composition comprising a fiber composition according to an embodiment of the present invention can have a total dissolution time of less than about 1000 seconds, less than about 750 seconds, less than about 500 seconds, less than about 250 seconds, about 50 seconds to about 250 seconds, or about 50 seconds to about 500 seconds per dose of oral care composition. According to the dissolution method described herein, a foam composition according to an embodiment of the present invention can have a total dissolution time of less than about 50 seconds, less than about 30 seconds, or less than about 20 seconds per dose of foam composition. Comparable paste formulations of dentifrice have a dissolution time of greater than 1000 seconds, which is not suitable for unit dose oral care compositions that need to be dissolved when in contact with moisture in the oral cavity.
[0275] Fluoride intake
[0276] Oral care compositions can be described according to their average fluoride uptake by HAP dissolution. Although oral care compositions according to embodiments of the present invention also contain components that are usually avoided or carefully avoided due to reactivity with fluoride ions, they have a higher average F uptake. For example, an oral care composition may have an average fluoride uptake of at least 1000ppm, at least 1500ppm, or at least 2000ppm, although it contains a fluoride ion source and a calcium ion source that can react to form precipitated calcium fluoride before being used by a consumer. Oral care compositions as described herein physically separate the fluoride ion source from the calcium ion source in different nonwoven fiber web layers, in separate parts, in separate compositions of the oral care composition, or in a soluble solid phase. The physical separation of these components has previously been difficult to achieve. Unit dose oral care compositions (such as pouches, solid foams, or soluble fiber compositions) provide a base structure that can physically separate fluoride ions from calcium ions during storage, but also allow them to be combined when dissolved and / or disintegrated in the oral cavity.
[0277] Tin ion uptake
[0278] Oral care compositions can be described according to their average tin ion uptake by HAP dissolution. Although oral care compositions according to embodiments of the present invention also include components that are usually avoided or carefully formulated due to reactivity with tin ions, they have a higher average Sn uptake. For example, oral care compositions may have an average tin ion uptake of at least 5000ppm, at least 10000ppm, or at least 20000ppm, although they include a tin ion source and polyphosphate, silica abrasive, etc. that can react to form a tin complex before being used by a consumer. Oral care compositions as described herein physically separate metal ion sources from polyphosphate, silica abrasive, or other chelating agents in different nonwoven fiber web layers, in separate parts, in separate compositions of oral care compositions, or in soluble solid phases. The physical separation of these components has previously been difficult to achieve. Unit dose oral care compositions (such as pouches, solid foams, or soluble fiber compositions) provide a base structure that can physically separate metal ions from other reactive components during storage, but also allow them to be combined when dissolved and / or disintegrated in the oral cavity.
[0279] form
[0280] As described herein, oral care compositions can be described by their morphology, which is unique relative to other oral care compositions (such as dentifrice pastes and / or mouthwashes). For example, a unit dose oral care composition comprising a fiber composition can be a nonwoven fiber web of fibers and / or filaments. A unit dose oral care composition comprising a solid soluble foam composition can have voids in a solid foam network connected by stays. The solid soluble foam composition can have an average void volume percentage of at least about 75%, at least about 85%, or at least about 88%, or a ratio between the total space occupied by the void space and the foam. In contrast, the fiber composition can have an average void volume of about 15% to about 75%, about 15% to about 70%, about 30% to about 75%, or about 35% to about 70%. Dentifrice pastes and / or mouthwashes will have an average void volume percentage of less than 15% before being used by consumers.
[0281] The solid dissolvable foam composition may have an average pore size of greater than about 0.1 mm, greater than about 0.2 mm, or greater than about 0.3 mm. In contrast, the fiber composition may have an average pore size of about 0.001 mm to about 0.1 mm, about 0.01 mm to about 0.05 mm, or about 0.01 mm to about 0.1 mm. Since the dentifrice paste and / or mouthwash is a liquid and / or paste, it is expected that the dentifrice paste and / or mouthwash will not have pores before being used by a consumer.
[0282] The solid soluble foam composition may have a thickness of about 50 mm -1 To about 150mm -1 、Approx. 75mm -1 To about 160mm -1 or about 100mm -1 To about 150mm -1 In contrast, the surface of the fiber composition may be at least about 150 mm -1 , at least about 200mm -1 Or at least about 250mm -1 .
[0283] Example
[0284] The following examples further describe and demonstrate embodiments within the scope of the present invention. These examples are provided for illustrative purposes only and should not be construed as limitations of the present invention, as many variations are possible without departing from the spirit and scope of the present invention. Unless otherwise indicated, all exemplified amounts are concentrations by weight of the total composition, i.e., wt / wt percentages.
[0285] Unit dose oral care composition
[0286] The fiber unit dose oral care composition is composed of a fiber composition and a non-fiber composition. Based on Table 1, the fiber composition is prepared by first adding USP water to a batch mixing tank. The target amount of water is 60% by weight, including water introduced with any aqueous components, so the actual amount of components added varies based on the batch size and the target composition. Next, the target amount of xylitol is added to the batch mixing tank while mixing at 60 rpm. The target amount of polyvinyl alcohol is added to the batch mixing tank. The batch mixing tank is heated to 80°C. The mixture is heated at 80°C and stirred at 120 rpm for 2 hours.
[0287] The target amounts of sodium lauryl sulfate and cocamidopropyl betaine were added sequentially as aqueous solutions. Next, sucralose was added to the mixture. Finally, a fluoride ion source was added if necessary. The fiber composition melt was allowed to degas overnight while stirring at 70°C.
[0288] The fiber composition melt is allowed to cool to 40°C and the fiber composition melt is spun into filaments and / or fibers. The fiber composition melt is transferred from the inter-batch mixing tank to a fiber spinning die. The fibers and / or filaments are extruded through a Biax-fiberfilm multi-row capillary die at 60°C. The fibers and / or filaments are attenuated and dried with hot air to have less than 5% moisture. The fibers and / or filaments are collected on a belt as a fiber composition.
[0289] The non-fibrous composition was synthesized by adding the components listed in Table 1 to PEG-12, using mechanical mixing to create a slurry.
[0290] The fiber unit dose composition is assembled by placing a first strip of fiber composition on a template. A cavity in the fiber composition is prepared by applying force within each die hole. A non-fiber composition is applied to the inside of the cavity with a dropper. A second strip of fiber composition is placed on top of the template. Pressure is applied to cut and bond the edges of the first fiber composition layer and the second fiber composition layer. The dose is removed from the die cutter and the process is repeated for each dose. The non-fiber composition in Examples 1 to 5 is completely surrounded by the fiber composition. For Example 1, the diameter of the fiber composition is about 0.69 inches, and the diameter of the non-fiber composition is about 0.63 inches.
[0291] Table 1. Unit dose oral care compositions
[0292]
[0293]
[0294] 1 powder
[0295] 2Mixture of PVA403 and PVA420H
[0296] Table 2. Reference dentifrice formulations
[0297] Inactive Ingredients Example 6 USP NaF Preparation Carbomer 0.300 0.300 Carboxymethyl cellulose 0.750 -- FD&C Blue 0.050 0.050 Flavoring 0.810 0.900 Silica hydrate 15.000 20.000 Saccharin Sodium 0.130 0.130 Sodium fluoride 0.111 0.243 Sodium lauryl sulfate solution (29%) 4.000 4.000 Sodium dihydrogen phosphate monohydrate 0.419 0.590 Sorbitol solution (70%) 65.641 60.172 Titanium Dioxide 0.525 0.525 Trisodium phosphate dodecahydrate 1.100 1.450 water 11.165 11.165 Xanthan gum -- 0.475
[0298] Table 3. List of ingredients of commercial preparations
[0299]
[0300]
[0301] Pharmacokinetics of salivary fluoride
[0302] Treatment Instructions and Saliva Collection Method
[0303] Healthy subjects are usually recruited. Eligible participants are at least 18 years old, have a minimum of 16 natural teeth, and an unstimulated saliva flow rate of 0.3 mL / min to 0.6 mL / min. Participants are asked not to change their current oral hygiene habits during each study, and a fluoride / silicon dioxide-free toothpaste (Burt's Bite Purely White) is provided to them on the night and morning before the study visit for their use at home to avoid fluoride residues. All treatments are performed in a clinical setting under the supervision of a dental professional. Pre-weighed mouthwash or toothpaste is provided to the subjects, and the product is used as directed.
[0304] During the treatment phase and under human supervision, subjects were asked to provide a baseline saliva sample by letting their saliva pool gently in their mouth before spitting into a pre-labeled collection bottle. After collecting the baseline saliva, subjects were instructed to brush their teeth for 2 minutes with the appropriate treatment.
[0305] Supervised brushing instructions for a conventional dentifrice composition are listed below. Subjects will brush their teeth with the indicated amount of fluoride dentifrice.
[0306] a) Set the timer for 2 minutes.
[0307] b) Move the toothbrush briefly across the mouth to distribute the toothpaste relatively evenly over each quadrant.
[0308] c) Start the timer as soon as you start brushing your teeth.
[0309] d) Start brushing in one quadrant. Continue brushing for exactly 30 seconds in each quadrant, 10 seconds on each surface (buccal, lingual, coronal), for a total brushing time of 2 minutes.
[0310] e) Pool the toothpaste slurry in front of the mouth and spit out all of the toothpaste in one motion.
[0311] f) Rinse with 10 mL of fluoride-free water, brushing gently for 10 seconds, equal time in each quadrant, and spitting in one motion.
[0312] Supervised brushing instructions for the dissolvable unit dose dentifrice composition are listed below. The investigator will wet the toothbrush, apply a single unit dose of dentifrice, and wet it with fluoride-free water for 3 seconds.
[0313] a) Set the timer for 2 minutes.
[0314] b) Move the toothbrush briefly across the mouth to distribute the toothpaste relatively evenly over each quadrant.
[0315] c) Start the timer as soon as you start brushing your teeth.
[0316] d) Start brushing in one quadrant. Continue brushing for exactly 30 seconds in each quadrant, 10 seconds on each surface (buccal, lingual, coronal), for a total brushing time of 2 minutes.
[0317] e) Pool the toothpaste slurry in front of the mouth and spit out all of the toothpaste in one motion.
[0318] f) Rinse with 10 mL of fluoride-free water, brushing gently for 10 seconds, equal time in each quadrant, and spitting in one motion.
[0319] The supervised brushing instructions for the compressed tablet unit dose dentifrice composition are listed below. Subjects placed the tablet unit dose in their mouth, crushed it between their teeth, and then brushed their teeth with a pre-moistened toothbrush.
[0320] a) Set the timer for 2 minutes.
[0321] b) Move the toothbrush briefly across the mouth to distribute the toothpaste relatively evenly over each quadrant.
[0322] c) Start the timer as soon as you start brushing your teeth.
[0323] d) Start brushing in one quadrant. Continue brushing for exactly 30 seconds in each quadrant, 10 seconds on each surface (buccal, lingual, coronal), for a total brushing time of 2 minutes.
[0324] e) Pool the toothpaste slurry in front of the mouth and spit out all of the toothpaste in one motion.
[0325] f) Rinse with 10 mL of fluoride-free water, brushing gently for 10 seconds, equal time in each quadrant, and spitting in one motion.
[0326] Two minutes before the collection time point after brushing, spitting and rinsing, instruct the subject to swallow, and start the timer immediately. Subjects allow their saliva to gather. While keeping 20 seconds until the collection time point, the panelists gently brush the saliva accumulated around each quadrant, 5 seconds for each quadrant. At the collection time point, in one action, the panelists will spit out the collected saliva into the collection bottle. Repeat the sample collection process at 2 minutes, 6 minutes, 12 minutes and 30 minutes after brushing. All samples were stored on laboratory ice for up to 6 hours, and then transported overnight on dry ice to freeze at -70 ° C until processing.
[0327] Sample preparation and analysis
[0328] Saliva samples were prepared and analyzed by filtration and dilution with water and then injected into an ion chromatograph using a commercially available analytical column for separation with suppressed conductivity detection. Results were calculated using a secondary calibration curve generated from a series of known fluoride standards.
[0329] All method parameters were developed and validated in accordance with the FDA's Guidance for Industry related to Bioanalytical Method Validation (2018), particularly as applied to chromatographic analysis. The fluoride analytical method has been validated to a level appropriate for the intended purpose of these developmental studies. Calibration standards and quality control (QC) samples were prepared in saliva matrix using NIST-traceable fluoride standard solutions. The working range of the method was established from approximately 3 ppb to approximately 100 ppb injected F ion. Selectivity was demonstrated, and saliva was shown to be free of interfering substances, with no matrix effects observed. The sensitivity of the method has been established to 3.13 ppb injected F ion, with a lower limit of quantitation (LLOQ) of 0.0783 ppm F ion in saliva. Freeze / thaw stability and critical solution stability were established at -70°C for 3 cycles and 6 weeks, respectively. Accuracy, precision, and recovery consistently met the acceptance criteria for both bioanalytical method validation and analytical recommendations in the study.
[0330] The analytical method sample preparation protocol was specifically developed to minimize handling and eliminate any potential sources of added fluoride or adsorption from consumable materials used in sample preparation. The analytical technique selected was ion chromatography because it provides high sensitivity without adding any reagents to the resulting sample that could potentially further release or suppress F ions. Saliva was simply passed through a 5μm PTFE filter and diluted with filtered DI water. Commercially available analytical columns were used in this method to ensure that the study method was accessible and reproducible in external laboratories. Samples were quantified against a calibration curve prepared by serial dilution of an F control in a saliva matrix. Daily method performance was verified by high-level, mid-level, and low-level QC analysis in accordance with FDA guidance.
[0331] Data fitting for salivary fluoride pK AUC calculation
[0332] The general approach is to fit the data points with an exponential decay curve with a constant intercept. Due to the exponential decay, there is little change in the salivary fluoride concentration values for data collected after 30 minutes. This approach greatly simplifies the data analysis but gives robust AUC results.
[0333] Due to the decaying nature of the salivary fluoride curve, AUC 2-t The AUC from 2 minutes until time t was considered the primary measure for evaluation. A 3-parameter first-order decay model curve (y = θ1 × exp(-θ2·X) + θ3) was fitted and then integrated to obtain the salivary fluoride pK AUC. The salivary fluoride pK AUC was calculated using SAS (version 9.3 or higher). ) at the available time points to fit the decay curve of each subject in each period; integrate the curve to obtain the AUC 2-30 All salivary fluoride pK studies were analyzed using this method.
[0334] The non-inferiority of the treatment groups was assessed using a generalized mixed model with treatment and period as fixed effects, baseline salivary fluoride value as a covariate, and subject as a random effect. The experimental treatment was considered non-inferior to the control (reference toothpaste) if the mean of the performance of the experimental treatment divided by the mean of the control treatment in the above model was higher than 60%. For the experiments discussed below, the treatment mass of the reference toothpaste was either 1 g or 1.25 g.
[0335] Table 4. Saliva pK AUC values
[0336]
[0337] The Example 6 composition in Table 4 uses the same therapeutic substance, but with a lower fluoride concentration. As expected, when comparing one toothpaste to another, the primary driver of efficacy is the fluoride concentration. In this case, the AUC for Example 6 is 46% of the AUC for the USP NaF Control, meaning that Example 6 performs inferior to the USP NaF Control. Interestingly, Example 1 has a much lower quality and a much higher fluoride concentration than the USP NaF Control. Unexpectedly, this very different therapeutic quality and active concentration produced non-inferior results relative to the USP NaF Control. This composition uses the same F dose as the USP NaF Control. However, providing the same dose of fluoride does not guarantee non-inferiority per unit dose.
[0338] Table 5. Saliva pK AUC values
[0339]
[0340] Table 5 shows the results of the comparison of Examples 1 to 5 (heterogeneous compositions) and Example 6 with the USP NaF control. Again, the performance of Example 6 in Table 5 is inferior to the USP NaF control. Example 5 in Table 5 also has a lower therapeutic mass and a higher fluoride concentration than the USP NaF control; however, the fluoride is distributed into the fiber composition, rather than the non-fiber concentration. Even though the fluoride dose is the same, distributing the fluoride in this manner results in the unit dose not being able to achieve non-inferior performance relative to the USP NaF control. The performance of Example 4 is not inferior to the USP NaF control, again despite having a much lower therapeutic mass and a much higher fluoride concentration than the USP NaF control. Interestingly, the performance of Example 3 and the performance of Example 2 are both inferior to the USP NaF control. In the case of both Examples 3 and 2, there is a higher fluoride concentration and a lower fluoride dose than the NaF control. It is apparent from these results that the distribution of fluoride within a heterogeneous unit dose composition can affect the delivery of fluoride to the mouth; however, the impact of fluoride distribution is difficult to determine in advance. The inclusion of the fluoride of Example 5 in a fiber element was intended to deliver the fluoride to the mouth more completely and more quickly. This was not achieved. Instead, and surprisingly, delivery was reduced. Furthermore, in the examples where the fluoride was distributed in a non-fibrous composition and the compositions had the same mass, the fluoride dose was not linearly proportional to the AUC. For example, Example 3 had a fluoride dose that was 77% of the fluoride dose of Example 4, but the AUC of Example 3 was about half that of Example 4.
[0341] Table 6. Saliva pK AUC values
[0342]
[0343] Table 6 shows Anywhere Anti-cavity Fluoride Tooth Tabs and the control Cavity protection compared to the results. Anywhere Anti-cavity Fluoride Tooth Tabs perform worse than Cavity Protection, even though the concentration of fluoride in Tooth Tabs matched that of the control. This is an important observation because Anywhere Anti-cavity Fluoride Tooth Tab delivers significantly less fluoride to the oral cavity, which may negatively impact the caries performance of this unit dosage form by reducing the therapeutic benefit that the consumer may receive.
[0344] Table 7. Saliva pK AUC values Experiment 2
[0345]
[0346] Table 7 shows the difference between Etee Chewpaste with Fluoride and the control The performance of Etee Chewpaste with Fluoride is inferior to CavityProtection, even though the fluoride concentration of the tablets was greater than that of the control. This is an important observation because Etee Chewpaste with Fluoride delivers much less fluoride to the oral cavity, which could negatively impact the caries performance of this unit dosage form by reducing the therapeutic benefit that the consumer could potentially receive.
[0347] In none of these examples is the fluoride concentration, therapeutic mass or fluoride dose itself sufficient to predict the measured salivary pK AUC of fluoride measured from 2 minutes to 30 minutes after brushing. The examples evaluated in Experiments 1 to 3 show that the release and dispersion of fluoride from an oral care composition can be significantly altered by (i) the presence of excipients, (ii) the dosage form, (iii) the concentration of fluoride, (iv) the dose of fluoride, (v) the distribution of fluoride in a heterogeneous composition, and (vi) the manufacturer's instructions for use. Therefore, the delivery of fluoride ions to the oral cavity of a solid or semisolid unit dose oral care composition may be lower than expected. These dependencies are difficult to predict in advance. The results herein demonstrate how to formulate a unit dose composition that delivers a non-inferior amount of fluoride to the oral cavity relative to a reference toothpaste, thereby helping to ensure effective anti-caries efficacy as a reference toothpaste.
[0348] Unless expressly excluded or otherwise limited, each document cited herein, including any cross-referenced or related patent or patent application and any patent application or patent to which this application claims priority or the benefit of, is hereby incorporated by reference in its entirety. The citation of any document is not an admission that it is prior art to any of the present invention disclosed or claimed herein, or an admission that it, by itself or in combination with any one or more of the references, proposes, suggests, or discloses any such invention. In addition, to the extent that any meaning or definition of a term in this invention conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this invention shall govern.
[0349] Although specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other changes and modifications may be made without departing from the spirit and scope of the present invention. Therefore, it is intended that all such changes and modifications within the scope of the present invention be covered in the appended claims.
Claims
1. A unit dose oral care composition, comprising: Fluoride and Salivary fluoride pK AUC, when the unit dose oral care composition is administered according to the manufacturer's instructions, the salivary fluoride pK AUC is from about 1 g to about 1.25 g At least 60% of the reference therapeutic quality of the control toothpaste within the range; Preferably wherein the unit dose oral care composition comprises greater than 850 ppm, greater than 1000 ppm, greater than 1150 ppm, greater than 1450 ppm, greater than 2000 ppm or greater than 3000 ppm fluoride.
2. The unit dose oral care composition of claim 1, wherein the fluoride comprises sodium fluoride, sodium monofluorophosphate, stannous fluoride, amine fluoride, or a combination thereof.
3. The unit dose oral care composition of claim 1 or 2, further comprising a metal.
4. A unit dose oral care composition according to claim 3, wherein the metal comprises tin, zinc or a combination thereof, preferably wherein the tin comprises stannous fluoride, stannous chloride, stannous pyrophosphate or a combination thereof, and / or preferably wherein the zinc comprises zinc citrate, zinc lactate, zinc oxide, zinc phosphate or a combination thereof.
5. A unit dose oral care composition according to any one of claims 1 to 4, further comprising from about 1% to about 50% by weight of the composition of one or more fiber web forming materials, preferably wherein the one or more fiber web forming materials comprise starch, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene oxide, carboxymethyl cellulose, polyacrylic acid, polyvinyl ether maleic acid copolymer, or a combination thereof.
6. The unit dose oral care composition of any one of claims 1 to 5, wherein the oral care composition has from about 0.01% to about 10% of the fluoride, by weight of the composition.
7. The unit dose oral care composition of any one of claims 1 to 6, wherein the oral care composition has a fluoride uptake of at least about 1500 ppm.
8. The unit dose oral care composition of any one of claims 1 to 7, further comprising about 0.01% by weight of the composition to about 40% of a calcium ion source, preferably wherein the calcium ion source is a calcium abrasive, a calcium salt or a combination thereof.
9. The unit dose oral care composition of any one of claims 1 to 8, wherein the salivary fluoride pK AUC is at least 65%, at least 70%, at least 75%, or at least 80% of a reference salivary fluoride pK AUC.
10. The unit dose oral care composition of any one of claims 1 to 9, wherein the unit dose oral care composition comprises a pouch, a droplet, a solid open-cell foam, a solid closed-cell foam, a fiber composition, a paste composition, a gel composition, a tablet composition, a bar composition, a ribbon composition, a disc composition, a wafer composition, or a combination thereof.
11. The unit dose oral care composition of any one of claims 1 to 11, further comprising a fibrous composition and a non-fibrous composition, the non-fibrous composition comprising the fluoride.
12. The unit dose oral care composition of any one of claims 1 to 11, wherein when the unit dose oral care composition comprises the fiber composition and the non-fibrous composition, the fiber composition extends beyond the perimeter of the non-fibrous composition, and preferably wherein the fiber composition extends beyond the perimeter of the non-fibrous composition by at least about 0.02 inches.
13. The unit dose oral care composition of any one of claims 1 to 11, wherein the unit dose oral care composition comprises a tablet.
